Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bacterial Infections and Mycoses

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 545 articles: HTML format

Single Articles

May 2024
1. BERGIN S, Doorley LA, Rybak JM, Wolfe KH, et al
   Analysis of clinical Candida parapsilosis isolates reveals copy number variation in key fluconazole resistance genes.
   Antimicrob Agents Chemother. 2024 May 7:e0161923. doi: 10.1128/aac.01619.
   PubMed     Abstract available
   
   
   
2. VEGA AD, DeRonde K, Jimenez A, Piazza M, et al
   Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-beta-lactamase (bla(VIM)): infection management and molecular analysis.
   Antimicrob Agents Chemother. 2024;68:e0147423.
   PubMed     Abstract available
   
   
   
3. KHALID SA, Abd Algaffar S, Tajuddeen N, Lombe BK, et al
   Naphthylisoquinoline alkaloids: novel agents against the causative pathogens of eumycetoma and actinomycetoma-en route to broad-spectrum antimycetomal drugs.
   Antimicrob Agents Chemother. 2024;68:e0161223.
   PubMed     Abstract available
   
   
   
4. HAYNES AS, Wei Z, Anderson P, Scheetz MH, et al
   Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections.
   Antimicrob Agents Chemother. 2024;68:e0018224.
   PubMed     Abstract available
   
   
   
5. MILLER AA, Moussa SH, McLeod SM
   Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK).
   Antimicrob Agents Chemother. 2024;68:e0169823.
   PubMed     Abstract available
   
   
   
6. MARTINS-GONCALVES T, Pimenta JS, Fontana H, Esposito F, et al
   Acinetobacter baumannii international clone 2 co-producing OXA-23, NDM-1, and ArmA emerging in South America.
   Antimicrob Agents Chemother. 2024;68:e0029824.
   PubMed    
   
   
   
7. CHEN L, Shashkina E, Kurepina N, Calado Nogueira de Moura V, et al
   In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus.
   Antimicrob Agents Chemother. 2024;68:e0017424.
   PubMed     Abstract available
   
   
   
8. GEBREMARIAM T, Alkhazraji S, Gu Y, Najvar LK, et al
   Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.
   Antimicrob Agents Chemother. 2024;68:e0154523.
   PubMed     Abstract available
   
   
   
9. PHAM J, Benefield RJ, Baker N, Lindblom S, et al
   In vitro activity of omadacycline against clinical isolates of Nocardia.
   Antimicrob Agents Chemother. 2024;68:e0168623.
   PubMed     Abstract available
   
   
   
10. MUHLEN S, Heroven AK, Elxnat B, Kahl S, et al
    Infection and antibiotic-associated changes in the fecal microbiota of C. rodentium varphistx2(dact)-infected C57BL/6 mice.
    Antimicrob Agents Chemother. 2024;68:e0005724.
    PubMed     Abstract available
    
    
    
11. BARCELO IM, Escobar-Salom M, Cabot G, Perello-Bauza P, et al
    Transferable AmpCs in Klebsiella pneumoniae: interplay with peptidoglycan recycling, mechanisms of hyperproduction, and virulence implications.
    Antimicrob Agents Chemother. 2024;68:e0131523.
    PubMed     Abstract available
    
    
    
12. SUZUKI D, Sakurai A, Wakuda M, Suzuki M, et al
    Clinical and genomic characteristics of IMP-producing Enterobacter cloacae complex and Klebsiella pneumoniae.
    Antimicrob Agents Chemother. 2024;68:e0167223.
    PubMed     Abstract available
    
    
    
13. NIELSEN TK, Petersen IB, Xu L, Barbuti MD, et al
    The Spx stress regulator confers high-level beta-lactam resistance and decreases susceptibility to last-line antibiotics in methicillin-resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 2024 May 1:e0033524. doi: 10.1128/aac.00335.
    PubMed     Abstract available
    
    
    
14. YU W, Ju Y, Han X, Tian X, et al
    Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2024 May 1:e0012424. doi: 10.1128/aac.00124.
    PubMed     Abstract available
    
    
    April 2024
15. BEN-SHMUEL A, Glinert I, Sittner A, Bar-David E, et al
    Doxycycline, levofloxacin, and moxifloxacin are superior to ciprofloxacin in treating anthrax meningitis in rabbits and NHP.
    Antimicrob Agents Chemother. 2024 Apr 30:e0161023. doi: 10.1128/aac.01610.
    PubMed     Abstract available
    
    
    
16. HARTUIS S, Ourliac-Garnier I, Robert E, Albassier M, et al
    Precise genome editing underlines the distinct contributions of mutations in ERG11, ERG3, MRR1, and TAC1 genes to antifungal resistance in Candida parapsilosis.
    Antimicrob Agents Chemother. 2024 Apr 16:e0002224. doi: 10.1128/aac.00022.
    PubMed     Abstract available
    
    
    
17. KENGO A, Nabeemeeah F, Denti P, Sabet R, et al
    Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 10:e0158323. doi: 10.1128/aac.01583.
    PubMed     Abstract available
    
    
    
18. LOSSOUARN J, Beurrier E, Bouteau A, Moncaut E, et al
    The virtue of training: extending phage host spectra against vancomycin-resistant Enterococcus faecium strains using the Appelmans method.
    Antimicrob Agents Chemother. 2024 Apr 9:e0143923. doi: 10.1128/aac.01439.
    PubMed     Abstract available
    
    
    
19. POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al
    Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 8:e0118523. doi: 10.1128/aac.01185.
    PubMed     Abstract available
    
    
    
20. WEI X, Gao J, Zhou D, Xu C, et al
    Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against Pseudomonas aeruginosa by enhancing membrane potential.
    Antimicrob Agents Chemother. 2024;68:e0153923.
    PubMed     Abstract available
    
    
    
21. ASLAM S, Roach D, Nikolich MP, Biswas B, et al
    Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases.
    Antimicrob Agents Chemother. 2024;68:e0172823.
    PubMed     Abstract available
    
    
    
22. GSCHWIND R, Petitjean M, Fournier C, Lao J, et al
    Inter-phylum circulation of a beta-lactamase-encoding gene: a rare but observable event.
    Antimicrob Agents Chemother. 2024;68:e0145923.
    PubMed     Abstract available
    
    
    
23. XUE J, Li W, Zhao Y, Wang L, et al
    Antibiotic-induced ROS-mediated Fur allosterism contributes to Helicobacter pylori resistance by inhibiting arsR activation of mutS and mutY.
    Antimicrob Agents Chemother. 2024;68:e0167923.
    PubMed     Abstract available
    
    
    
24. RIBEIRO DOS SANTOS A, Gade L, Misas E, Litvintseva AP, et al
    Bimodal distribution of azole susceptibility in Sporothrix brasiliensis isolates in Brazil.
    Antimicrob Agents Chemother. 2024;68:e0162023.
    PubMed     Abstract available
    
    
    
25. TAIT JR, Anderson D, Nation RL, Creek DJ, et al
    Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2024;68:e0108123.
    PubMed     Abstract available
    
    
    
26. YANO H, Hayashi W, Kawakami S, Aoki S, et al
    Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan.
    Antimicrob Agents Chemother. 2024 Apr 2:e0166923. doi: 10.1128/aac.01669.
    PubMed     Abstract available
    
    
    March 2024
27. LOCKE JB, Pillar CM, Castanheira M, Carvalhaes CG, et al
    Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
    Antimicrob Agents Chemother. 2024 Mar 25:e0158423. doi: 10.1128/aac.01584.
    PubMed     Abstract available
    
    
    
28. MAIA AR, Cezard A, Fouquenet D, Vasseur V, et al
    Preventive nasal administration of flagellin restores antimicrobial effect of gentamicin and protects against a multidrug-resistant strain of Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2024 Mar 25:e0136123. doi: 10.1128/aac.01361.
    PubMed     Abstract available
    
    
    
29. SEGAWA T, Masuda K, Hisatsune J, Ishida-Kuroki K, et al
    Genomic analysis of inter-hospital transmission of vancomycin-resistant Enterococcus faecium sequence type 80 isolated during an outbreak in Hiroshima, Japan.
    Antimicrob Agents Chemother. 2024 Mar 20:e0171623. doi: 10.1128/aac.01716.
    PubMed     Abstract available
    
    
    
30. SUN L, Zhuang H, Chen M, Chen Y, et al
    Vancomycin heteroresistance caused by unstable tandem amplifications of the vanM gene cluster on linear conjugative plasmids in a clinical Enterococcus faecium.
    Antimicrob Agents Chemother. 2024 Mar 20:e0115923. doi: 10.1128/aac.01159.
    PubMed     Abstract available
    
    
    
31. LYONS MA, Obregon-Henao A, Ramey ME, Bauman AA, et al
    Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
    Antimicrob Agents Chemother. 2024 Mar 19:e0101023. doi: 10.1128/aac.01010.
    PubMed     Abstract available
    
    
    
32. VILLELLAS C, Stevenaert F, Remmerie B, Andries K, et al
    Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium tuberculosis mutants with increased MIC.
    Antimicrob Agents Chemother. 2024 Mar 12:e0127523. doi: 10.1128/aac.01275.
    PubMed     Abstract available
    
    
    
33. HILLIARD JJ, Jakielaszek C, Mannino F, Hossain M, et al
    Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax.
    Antimicrob Agents Chemother. 2024;68:e0149723.
    PubMed     Abstract available
    
    
    
34. HOSODA K, Koyama N, Shigeno S, Nishimura T, et al
    Mavintramycin A is a promising antibiotic for treating Mycobacterium avium complex infectious disease.
    Antimicrob Agents Chemother. 2024;68:e0091723.
    PubMed     Abstract available
    
    
    
35. ZHANG X, Wang Y, Li S, Xie F, et al
    Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem.
    Antimicrob Agents Chemother. 2024;68:e0154123.
    PubMed     Abstract available
    
    
    
36. ANDRE C, Van Camp AG, Ung L, Gilmore MS, et al
    Characterization of the resistome and predominant genetic lineages of Gram-positive bacteria causing keratitis.
    Antimicrob Agents Chemother. 2024;68:e0124723.
    PubMed     Abstract available
    
    
    
37. DUREJA C, Rutherford JT, Pavel FB, Norseeda K, et al
    In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy.
    Antimicrob Agents Chemother. 2024;68:e0122223.
    PubMed     Abstract available
    
    
    
38. SALILLAS S, Raaijmakers J, Aarnoutse RE, Svensson EM, et al
    Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model.
    Antimicrob Agents Chemother. 2024;68:e0115723.
    PubMed     Abstract available
    
    
    
39. KOTTOM TJ, Carmona EM, Limper AH
    Characterization of the Pneumocystis jirovecii and Pneumocystis murina phosphoglucomutases (Pgm2s): a potential target for Pneumocystis therapy.
    Antimicrob Agents Chemother. 2024;68:e0075623.
    PubMed     Abstract available
    
    
    
40. CARUSO L, Mellini M, Catalano Gonzaga O, Astegno A, et al
    Hydrogen sulfide production does not affect antibiotic resistance in Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2024 Mar 6:e0007524. doi: 10.1128/aac.00075.
    PubMed     Abstract available
    
    
    February 2024
41. SARANGI J, Ido A, Ito M, Iinuma C, et al
    Clinical isolates of Streptococcus mitis/oralis-related species with reduced carbapenem susceptibility, harboring amino acid substitutions in penicillin-binding proteins in Japan.
    Antimicrob Agents Chemother. 2024 Feb 28:e0117923. doi: 10.1128/aac.01179.
    PubMed     Abstract available
    
    
    
42. OLIVENCA F, Pires D, Silveiro C, Gama B, et al
    Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Feb 27:e0158623. doi: 10.1128/aac.01586.
    PubMed     Abstract available
    
    
    
43. LI S-Y, Tyagi S, Soni H, Betoudji F, et al
    Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2024 Feb 20:e0156223. doi: 10.1128/aac.01562.
    PubMed     Abstract available
    
    
    
44. TRUONG-BOLDUC QC, Wang Y, Ferrer-Espada R, Reedy JL, et al
    Staphylococcus aureus AbcA transporter enhances persister formation under beta-lactam exposure.
    Antimicrob Agents Chemother. 2024 Feb 16:e0134023. doi: 10.1128/aac.01340.
    PubMed     Abstract available
    
    
    
45. BASSERES E, Eubank TA, Begum K, Alam MJ, et al
    Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile.
    Antimicrob Agents Chemother. 2024 Feb 16:e0162123. doi: 10.1128/aac.01621.
    PubMed     Abstract available
    
    
    
46. ERSOY SC, Proctor RA, Rose WE, Abdelhady W, et al
    Sensitizing methicillin-resistant Staphylococcus aureus (MRSA) to cefuroxime: the synergic effect of bicarbonate and the wall teichoic acid inhibitor ticlopidine.
    Antimicrob Agents Chemother. 2024 Feb 13:e0162723. doi: 10.1128/aac.01627.
    PubMed     Abstract available
    
    
    
47. ORTIZ DE LA ROSA JM, Martin-Gutierrez G, Casimiro-Soriguer CS, Gimeno-Gascon MA, et al
    C-terminal deletion of RelA protein is suggested as a possible cause of infective endocarditis recurrence with Enterococcus faecium.
    Antimicrob Agents Chemother. 2024 Feb 13:e0108323. doi: 10.1128/aac.01083.
    PubMed     Abstract available
    
    
    
48. FLEMING D, Bozyel I, Ozdemir D, Otero JA, et al
    HOCl-producing electrochemical bandage for treating Pseudomonas aeruginosa-infected murine wounds.
    Antimicrob Agents Chemother. 2024;68:e0121623.
    PubMed     Abstract available
    
    
    
49. ANTONELLI A, Coppi M, Bonaiuto C, Giovacchini N, et al
    Novel resistance ICEs carrying the bla(FIM-1) metallo-beta-lactamase gene from an ST235 Pseudomonas aeruginosa sublineage.
    Antimicrob Agents Chemother. 2024;68:e0120523.
    PubMed     Abstract available
    
    
    
50. KOTTOM TJ, Carmona EM, Limper AH
    Targeting host tyrosine kinase receptor EphA2 signaling via small-molecule ALW-II-41-27 inhibits macrophage pro-inflammatory signaling responses to Pneumocystis carinii beta-glucans.
    Antimicrob Agents Chemother. 2024;68:e0081123.
    PubMed     Abstract available
    
    
    
51. MCDONALD RA, Nagy SG, Chambers M, Broberg CA, et al
    Nitric oxide-releasing prodrug for the treatment of complex Mycobacterium abscessus infections.
    Antimicrob Agents Chemother. 2024;68:e0132723.
    PubMed     Abstract available
    
    
    
52. PITOUT JDD, Peirano G, Matsumura Y, DeVinney R, et al
    Escherichia coli sequence type 410 with carbapenemases: a paradigm shift within E. coli toward multidrug resistance.
    Antimicrob Agents Chemother. 2024;68:e0133923.
    PubMed     Abstract available
    
    
    
53. MARTISCHANG R, Seth-Smith H, Verschuuren TD, Hequet D, et al
    Regional spread of an atypical ESBL-producing Escherichia coli ST131H89 clone among different human and environmental reservoirs in Western Switzerland.
    Antimicrob Agents Chemother. 2024;68:e0092523.
    PubMed     Abstract available
    
    
    
54. LEPAK AJ, VanScoy B, Rubino C, Ambrose PG, et al
    In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model.
    Antimicrob Agents Chemother. 2024 Feb 6:e0163123. doi: 10.1128/aac.01631.
    PubMed     Abstract available
    
    
    
55. CARUGATI M, Arif S, Yarrington ME, King LY, et al
    Limitations of antifungal prophylaxis in preventing invasive Candida surgical site infections after liver transplant surgery.
    Antimicrob Agents Chemother. 2024 Feb 1:e0127923. doi: 10.1128/aac.01279.
    PubMed     Abstract available
    
    
    January 2024
56. AXELL-HOUSE DB, Simar SR, Panesso D, Rincon S, et al
    LiaX is a surrogate marker for cell envelope stress and daptomycin non-susceptibility in Enterococcus faecium.
    Antimicrob Agents Chemother. 2024 Jan 30:e0106923. doi: 10.1128/aac.01069.
    PubMed     Abstract available
    
    
    
57. JIANG X, Li D, Sun Z, Lu Y, et al
    Type I BREX system defends against antibiotic-resistant plasmids in Escherichia coli.
    Antimicrob Agents Chemother. 2024 Jan 30:e0112823. doi: 10.1128/aac.01128.
    PubMed     Abstract available
    
    
    
58. IOVLEVA A, McElheny CL, Fowler EL, Cober E, et al
    In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.
    Antimicrob Agents Chemother. 2024 Jan 30:e0125823. doi: 10.1128/aac.01258.
    PubMed     Abstract available
    
    
    
59. LIU X, Wang Y, Chang W, Dai Y, et al
    AgrA directly binds to the promoter of vraSR and downregulates its expression in Staphylococcus aureus.
    Antimicrob Agents Chemother. 2024 Jan 23:e0089323. doi: 10.1128/aac.00893.
    PubMed     Abstract available
    
    
    
60. CHEN F, Yin Y, Chen H, Wang R, et al
    Global genetic diversity and Asian clades evolution: a phylogeographic study of Staphylococcus aureus sequence type 5.
    Antimicrob Agents Chemother. 2024 Jan 23:e0117523. doi: 10.1128/aac.01175.
    PubMed     Abstract available
    
    
    
61. TRUONG-BOLDUC QC, Yonker LM, Wang Y, Lawton BG, et al
    NorA efflux pump mediates Staphylococcus aureus response to Pseudomonas aeruginosa pyocyanin toxicity.
    Antimicrob Agents Chemother. 2024 Jan 17:e0100123. doi: 10.1128/aac.01001.
    PubMed     Abstract available
    
    
    
62. ALDEJOHANN AM, Menner C, Thielemann N, Martin R, et al
    In vitro activity of ibrexafungerp against clinically relevant echinocandin-resistant Candida strains.
    Antimicrob Agents Chemother. 2024 Jan 11:e0132423. doi: 10.1128/aac.01324.
    PubMed     Abstract available
    
    
    
63. PEARLMUTTER BS, Carlisle MG, Wilson BM, Sangwan N, et al
    Pulsed dosing and extended daily dosing of oral vancomycin do not facilitate clearance of Clostridioides difficile colonization in mice.
    Antimicrob Agents Chemother. 2024;68:e0090323.
    PubMed     Abstract available
    
    
    
64. WANG X, Chen L, Ruan H, Xiong Z, et al
    Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.
    Antimicrob Agents Chemother. 2024;68:e0077823.
    PubMed     Abstract available
    
    
    
65. GHASSANI A, Triponney P, Bour M, Plesiat P, et al
    Mutations in genes lpxL1, bamA, and pmrB impair the susceptibility of cystic fibrosis strains of Pseudomonas aeruginosa to murepavadin.
    Antimicrob Agents Chemother. 2024;68:e0129823.
    PubMed     Abstract available
    
    
    
66. BREIDENSTEIN EBM, Khan N, Duffy T, Coward C, et al
    SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae.
    Antimicrob Agents Chemother. 2024;68:e0069523.
    PubMed     Abstract available
    
    
    
67. BERMUDEZ TA, Brannon JR, Dudipala N, Reasoner S, et al
    Raising the alarm: fosfomycin resistance associated with non-susceptible inner colonies imparts no fitness cost to the primary bacterial uropathogen.
    Antimicrob Agents Chemother. 2024;68:e0080323.
    PubMed     Abstract available
    
    
    
68. TERAN N, Egge SL, Phe K, Baptista RP, et al
    The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.
    Antimicrob Agents Chemother. 2024;68:e0100923.
    PubMed     Abstract available
    
    
    
69. NOVY E, Abdul-Aziz MH, Cheng V, Burrows F, et al
    Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
    Antimicrob Agents Chemother. 2024;68:e0120123.
    PubMed     Abstract available
    
    
    
70. GOMIS-FONT MA, Clari MA, Lopez-Causape C, Navarro D, et al
    Emergence of cefiderocol resistance during ceftazidime/avibactam treatment caused by a large genomic deletion, including ampD and piuCD genes, in Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2024;68:e0119223.
    PubMed     Abstract available
    
    
    
71. KIRKLAND ME, Patfield S, Hughes AC, Hernlem B, et al
    A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.
    Antimicrob Agents Chemother. 2024;68:e0059823.
    PubMed     Abstract available
    
    
    
72. ARAGAW WW, Negatu DA, Bungard CJ, Dartois VA, et al
    Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2024;68:e0071723.
    PubMed     Abstract available
    
    
    
73. CHEN T, Yao J, Quan K, Xu J, et al
    Repurposing a human acetyl-CoA carboxylase inhibitor firsocostat to treat fungal candidiasis alone and in combination.
    Antimicrob Agents Chemother. 2024;68:e0113123.
    PubMed     Abstract available
    
    
    
74. SINGH P, Kumar A, Sharma P, Chugh S, et al
    Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Jan 9:e0076623. doi: 10.1128/aac.00766.
    PubMed     Abstract available
    
    
    
75. TAYLOR E, Nailor MD, Feider M, Sullivan S, et al
    Doxycycline versus cephalexin treatment of presumed streptococcal skin and soft tissue infection among adults presenting to the emergency department.
    Antimicrob Agents Chemother. 2024 Jan 3:e0128223. doi: 10.1128/aac.01282.
    PubMed     Abstract available
    
    
    December 2023
76. RUELAS CASTILLO J, Neupane P, Karanika S, Krug S, et al
    The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model.
    Antimicrob Agents Chemother. 2023 Dec 22:e0104323. doi: 10.1128/aac.01043.
    PubMed     Abstract available
    
    
    
77. SINGH S, Gumbo T, Boorgula GD, Thomas TA, et al
    Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model.
    Antimicrob Agents Chemother. 2023 Dec 22:e0108023. doi: 10.1128/aac.01080.
    PubMed     Abstract available
    
    
    
78. ALI AM, P Solans B, Hesseling AC, Winckler J, et al
    Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2023 Dec 19:e0079423. doi: 10.1128/aac.00794.
    PubMed     Abstract available
    
    
    
79. STEMKENS R, Cobussen M, de Laat E, Hoefsloot W, et al
    Successful addition of topical antibiotic treatment after surgery in treatment-refractory nontuberculous mycobacterial skin and soft tissue infections.
    Antimicrob Agents Chemother. 2023;67:e0078823.
    PubMed     Abstract available
    
    
    
80. ROEPCKE S, Passarell J, Walker H, Flanagan S, et al
    Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.
    Antimicrob Agents Chemother. 2023;67:e0091623.
    PubMed     Abstract available
    
    
    
81. NGUYEN DC, Buettner AM, Dousa KM
    Case Commentary: Another prong of attack? Topical antibiotic instillation with negative pressure wound therapy for nontuberculous mycobacterial skin and soft tissue infections.
    Antimicrob Agents Chemother. 2023;67:e0104823.
    PubMed     Abstract available
    
    
    
82. ROHANI R, Yarnold PR, Scheetz MH, Neely MN, et al
    Individual meropenem epithelial lining fluid and plasma PK/PD target attainment.
    Antimicrob Agents Chemother. 2023;67:e0072723.
    PubMed     Abstract available
    
    
    
83. KADO J, Salman S, Hla TK, Enkel S, et al
    Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study.
    Antimicrob Agents Chemother. 2023;67:e0096223.
    PubMed     Abstract available
    
    
    
84. LERMINIAUX N, Mitchell R, Bartoszko J, Davis I, et al
    Plasmid genomic epidemiology of bla(KPC) carbapenemase-producing Enterobacterales in Canada, 2010-2021.
    Antimicrob Agents Chemother. 2023;67:e0086023.
    PubMed     Abstract available
    
    
    
85. FERNANDEZ LEDESMA B, Mendoza-Palomar N, Melendo Perez S, Fernandez-Polo A, et al
    Isavuconazole use and TDM in real-world pediatric practice.
    Antimicrob Agents Chemother. 2023;67:e0082923.
    PubMed     Abstract available
    
    
    
86. COBIAN GUEMES AG, Ghatbale P, Blanc AN, Morgan CJ, et al
    Jumbo phages are active against extensively drug-resistant eyedrop-associated Pseudomonas aeruginosa infections.
    Antimicrob Agents Chemother. 2023;67:e0065423.
    PubMed     Abstract available
    
    
    
87. SASONI N, Caracciolo B, Cabeza MS, Gamarra S, et al
    Antifungal susceptibility testing following the CLSI M27 document, along with the measurement of MFC/MIC ratio, could be the optimal approach to detect amphotericin B resistance in Clavispora (Candida) lusitaniae. Susceptibility patterns of contempora
    Antimicrob Agents Chemother. 2023 Dec 12:e0096823. doi: 10.1128/aac.00968.
    PubMed     Abstract available
    
    
    
88. JAROMIN A, Zarnowski R, Markowski A, Zagorska A, et al
    Liposomal formulation of a new antifungal hybrid compound provides protection against Candida auris in the ex vivo skin colonization model.
    Antimicrob Agents Chemother. 2023 Dec 11:e0095523. doi: 10.1128/aac.00955.
    PubMed     Abstract available
    
    
    
89. LIU S, Huang Y, Jensen S, Laman P, et al
    Molecular physiological characterization of the dynamics of persister formation in Staphylococcus aureus.
    Antimicrob Agents Chemother. 2023 Dec 5:e0085023. doi: 10.1128/aac.00850.
    PubMed     Abstract available
    
    
    
90. HAN D, Ji Y, Yang S, Song P, et al
    Therapeutic effect of iturin A on Candida albicans oral infection and its pathogenic factors.
    Antimicrob Agents Chemother. 2023 Dec 5:e0094823. doi: 10.1128/aac.00948.
    PubMed     Abstract available
    
    
    
91. PANDEY S, Vilcheze C, Werngren J, Bainomugisa A, et al
    Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2023 Dec 1:e0109623. doi: 10.1128/aac.01096.
    PubMed     Abstract available
    
    
    November 2023
92. ZHAO J, Pu D, Li Z, Liu X, et al
    In vitro activity of cefiderocol, a siderophore cephalosporin, against carbapenem-resistant hypervirulent Klebsiella pneumoniae in China.
    Antimicrob Agents Chemother. 2023 Nov 28:e0073523. doi: 10.1128/aac.00735.
    PubMed     Abstract available
    
    
    
93. JIAO F, Bao Y, Li M, Zhang Y, et al
    Unraveling the mechanism of ceftaroline-induced allosteric regulation in penicillin-binding protein 2a: insights for novel antibiotic development against methicillin-resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 2023 Nov 16:e0089523. doi: 10.1128/aac.00895.
    PubMed     Abstract available
    
    
    
94. VAN DER LAAN LE, Garcia-Prats AJ, McIlleron H, Abdelwahab MT, et al
    Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2023 Nov 16:e0061123. doi: 10.1128/aac.00611.
    PubMed     Abstract available
    
    
    
95. SVISHCHUK J, Ebbert K, Waddell B, Izydorczyk C, et al
    Epidemiology and impact of methicillin-sensitive Staphylococcus aureus with beta-lactam antibiotic inoculum effects in adults with cystic fibrosis.
    Antimicrob Agents Chemother. 2023 Nov 15:e0013623. doi: 10.1128/aac.00136.
    PubMed     Abstract available
    
    
    
96. LANNI F, Antilus Sainte R, Hansen M Jr, Parigi P, et al
    A preclinical model of TB meningitis to determine drug penetration and activity at the sites of disease.
    Antimicrob Agents Chemother. 2023 Nov 15:e0067123. doi: 10.1128/aac.00671.
    PubMed     Abstract available
    
    
    
97. ALMEIDA D, Li S-Y, Lee J, Hafkin B, et al
    Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2023 Nov 15:e0078923. doi: 10.1128/aac.00789.
    PubMed     Abstract available
    
    
    
98. DIAZ-GARCIA J, Machado M, Alcala L, Reigadas E, et al
    Trends in antifungal resistance in Candida from a multicenter study conducted in Madrid (CANDIMAD study): fluconazole-resistant C. parapsilosis spreading has gained traction in 2022.
    Antimicrob Agents Chemother. 2023;67:e0098623.
    PubMed     Abstract available
    
    
    
99. CASADO A, Gimeno A, Aguilar-Guisado M, Garcia M, et al
    Safety of early oral ambulatory treatment of adult patients with bloodstream infections discharged from the emergency department.
    Antimicrob Agents Chemother. 2023;67:e0078023.
    PubMed     Abstract available
    
    
    
100. RUIZ VH, Fratoni A, Nicolau DP, Kuti JL, et al
     In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
     Antimicrob Agents Chemother. 2023;67:e0092023.
     PubMed     Abstract available
     
     
     
101. HARDY ME, Kenney RM, Tibbetts RJ, Shallal AB, et al
     Leveraging stewardship to promote ceftriaxone use in severe infections with low- and no-risk AmpC Enterobacterales.
     Antimicrob Agents Chemother. 2023;67:e0082623.
     PubMed     Abstract available
     
     
     
102. EL GHALI A, Stamper K, Kunz Coyne AJ, Holger D, et al
     Ciprofloxacin in combination with bacteriophage cocktails against multi-drug resistant Pseudomonas aeruginosa in ex vivo simulated endocardial vegetation models.
     Antimicrob Agents Chemother. 2023;67:e0072823.
     PubMed     Abstract available
     
     
     
103. SCHILDKRAUT JA, Raaijmakers J, Aarnoutse R, Hoefsloot W, et al
     The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease.
     Antimicrob Agents Chemother. 2023;67:e0087423.
     PubMed     Abstract available
     
     
     
104. LIM SY, Kwon HJ, Lee YW, Sung H, et al
     Routine ophthalmologic examination in Klebsiella pneumoniae bacteremia is not necessary: incidence of and risk factors for ocular involvement.
     Antimicrob Agents Chemother. 2023;67:e0082223.
     PubMed     Abstract available
     
     
     
105. HOLGER DJ, El Ghali A, Bhutani N, Lev KL, et al
     Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models.
     Antimicrob Agents Chemother. 2023;67:e0057823.
     PubMed     Abstract available
     
     
     
106. HALL RG 2ND, Liu S, Putnam WC, Kallem R, et al
     Optimizing anidulafungin exposure across a wide adult body size range.
     Antimicrob Agents Chemother. 2023;67:e0082023.
     PubMed     Abstract available
     
     
     
107. JUNG J, Chong YP, Lee HJ, Shim TS, et al
     Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type Mycobacterium avium complex pulmonary disease in relation to sputum smear results: a retrospective cohort study.
     Antimicrob Agents Chemother. 2023;67:e0100323.
     PubMed     Abstract available
     
     
     
108. ERB T, Mihai S, Strauss R, Herbst L, et al
     beta-(1-->3)-D-glucan- and mannan-guided early termination of antifungal therapy in ICU patients: a randomized controlled study.
     Antimicrob Agents Chemother. 2023;67:e0072523.
     PubMed     Abstract available
     
     
     
109. MUSICK WL
     Case Commentary: An espresso, a free puppy, and multidrug-resistant Campylobacter.
     Antimicrob Agents Chemother. 2023;67:e0075223.
     PubMed     Abstract available
     
     
     
110. BAO X, Goeteyn E, Crabbe A, Coenye T, et al
     Effect of malate on the activity of ciprofloxacin against Pseudomonas aeruginosa in different in vivo and in vivo-like infection models.
     Antimicrob Agents Chemother. 2023;67:e0068223.
     PubMed     Abstract available
     
     
     
111. HUANG L, Li Y, Xu C, Zhou M, et al
     A novel virulence plasmid encoding yersiniabactin, salmochelin, and RmpADC from hypervirulent Klebsiella pneumoniae of distinct genetic backgrounds.
     Antimicrob Agents Chemother. 2023;67:e0093523.
     PubMed     Abstract available
     
     
     
112. LI Y, Fang L, Dong M, Cai H, et al
     bla (KPC-2) overexpression and bla (GES-5) carriage as major imipenem/relebactam resistance mechanisms in Pseudomonas aeruginosa high-risk clones ST463 and ST235, respectively, in China.
     Antimicrob Agents Chemother. 2023;67:e0067523.
     PubMed     Abstract available
     
     
     
113. TIAN Z-X, Wang Y-P
     Identification of cpxS mutational resistome in Pseudomonas aeruginosa.
     Antimicrob Agents Chemother. 2023;67:e0092123.
     PubMed     Abstract available
     
     
     
114. MENSAH E, Fourie PB, Peters RPH
     Antimicrobial effects of Medicines for Malaria Venture Pathogen Box compounds on strains of Neisseria gonorrhoeae.
     Antimicrob Agents Chemother. 2023;67:e0034823.
     PubMed     Abstract available
     
     
     October 2023
115. JIANG S, Chen M, Zhang J, Ba X, et al
     Profiling daptomycin resistance among diverse methicillin-resistant Staphylococcus aureus lineages in China.
     Antimicrob Agents Chemother. 2023 Oct 30:e0056323. doi: 10.1128/aac.00563.
     PubMed     Abstract available
     
     
     
116. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
     Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
     Antimicrob Agents Chemother. 2023 Oct 26:e0073723. doi: 10.1128/aac.00737.
     PubMed     Abstract available
     
     
     
117. XIE YL, Modi N, Handler D, Yu S, et al
     Simplified urine-based method to detect rifampin underexposure in adults with tuberculosis: a prospective diagnostic accuracy study.
     Antimicrob Agents Chemother. 2023 Oct 25:e0093223. doi: 10.1128/aac.00932.
     PubMed     Abstract available
     
     
     
118. EL GHALI A, Morrisette T, Alosaimy S, Lucas K, et al
     Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes.
     Antimicrob Agents Chemother. 2023;67:e0082423.
     PubMed     Abstract available
     
     
     
119. MUNZEN ME, Reguera Gomez M, Hamed MF, Enriquez V, et al
     Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosis in vivo.
     Antimicrob Agents Chemother. 2023;67:e0045923.
     PubMed     Abstract available
     
     
     
120. GIAMBERARDINO CD, Tenor JL, Toffaletti DL, Palmucci JR, et al
     Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis.
     Antimicrob Agents Chemother. 2023;67:e0081823.
     PubMed     Abstract available
     
     
     
121. SNYDMAN DR, McDermott LA, Thorpe CM, Goldstein EJC, et al
     A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021.
     Antimicrob Agents Chemother. 2023;67:e0034923.
     PubMed     Abstract available
     
     
     
122. ALLAIN M, Maherault AC, Gachet B, Martinez C, et al
     Dissemination of IncI plasmid encoding bla (CTX-M-1) is not hampered by its fitness cost in the pig's gut.
     Antimicrob Agents Chemother. 2023;67:e0011123.
     PubMed     Abstract available
     
     
     
123. DEROCHE L, Aranzana-Climent V, Rozenholc A, Prouvensier L, et al
     Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling.
     Antimicrob Agents Chemother. 2023;67:e0048023.
     PubMed     Abstract available
     
     
     
124. AUBRY R, Buyck J, Prouvensier L, Decousser J-W, et al
     An improved PKPD modeling approach to characterize the pharmacodynamic interaction over time between ceftazidime/avibactam and colistin from in vitro time-kill experiments against multidrug-resistant Klebsiella pneumoniae isolates.
     Antimicrob Agents Chemother. 2023;67:e0030123.
     PubMed     Abstract available
     
     
     
125. HIGGS C, Kumar LS, Stevens K, Strachan J, et al
     Comparison of contemporary invasive and non-invasive Streptococcus pneumoniae isolates reveals new insights into circulating anti-microbial resistance determinants.
     Antimicrob Agents Chemother. 2023 Oct 12:e0078523. doi: 10.1128/aac.00785.
     PubMed     Abstract available
     
     
     
126. LAU JZ, Kuo SH, Belo Y, Malach E, et al
     Antibacterial efficacy of an ultra-short palmitoylated random peptide mixture in mouse models of infection by carbapenem-resistant Klebsiella pneumoniae.
     Antimicrob Agents Chemother. 2023 Oct 11:e0057423. doi: 10.1128/aac.00574.
     PubMed     Abstract available
     
     
     
127. KUHBACHER A, Merschak P, Haas H, Liebl M, et al
     The cytochrome P450 reductase CprA is a rate-limiting factor for Cyp51A-mediated azole resistance in Aspergillus fumigatus.
     Antimicrob Agents Chemother. 2023 Oct 10:e0091823. doi: 10.1128/aac.00918.
     PubMed     Abstract available
     
     
     
128. RAMEY ME, Kaya F, Bauman AA, Massoudi LM, et al
     Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.
     Antimicrob Agents Chemother. 2023 Oct 4:e0059723. doi: 10.1128/aac.00597.
     PubMed     Abstract available
     
     
     September 2023
129. STEMKENS R, Jager V, Dawson R, Diacon AH, et al
     Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
     Antimicrob Agents Chemother. 2023 Sep 28:e0068323. doi: 10.1128/aac.00683.
     PubMed     Abstract available
     
     
     
130. AGUILERA-CORREA JJ, Boudehen YM, Kremer L
     Characterization of Mycobacterium abscessus colony-biofilms based on bi-dimensional images.
     Antimicrob Agents Chemother. 2023;67:e0040223.
     PubMed     Abstract available
     
     
     
131. XIE M, Ganapathy US, Lan T, Osiecki P, et al
     ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant M. abscessus in caseum surrogate.
     Antimicrob Agents Chemother. 2023;67:e0038123.
     PubMed     Abstract available
     
     
     
132. MIRON-OCAMPO A, Beattie SR, Guin S, Conway T, et al
     CWHM-974 is a fluphenazine derivative with improved antifungal activity against Candida albicans due to reduced susceptibility to multidrug transporter-mediated resistance mechanisms.
     Antimicrob Agents Chemother. 2023 Sep 13:e0056723. doi: 10.1128/aac.00567.
     PubMed     Abstract available
     
     
     
133. HAYAKAWA K, Matsumura Y, Uemura K, Tsuzuki S, et al
     Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
     Antimicrob Agents Chemother. 2023 Sep 13:e0051023. doi: 10.1128/aac.00510.
     PubMed     Abstract available
     
     
     
134. NGUYEN HT, Venter H, Woolford L, Young KA, et al
     Oral administration of a 2-aminopyrimidine robenidine analogue (NCL195) significantly reduces Staphylococcus aureus infection and reduces Escherichia coli infection in combination with sub-inhibitory colistin concentrations in a bioluminescent mouse m
     Antimicrob Agents Chemother. 2023 Sep 11:e0042423. doi: 10.1128/aac.00424.
     PubMed     Abstract available
     
     
     
135. PODOLL JD, Rosen E, Wang W, Gao Y, et al
     A small-molecule membrane fluidizer re-sensitizes methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics.
     Antimicrob Agents Chemother. 2023 Sep 8:e0005123. doi: 10.1128/aac.00051.
     PubMed     Abstract available
     
     
     
136. MEIKLE V, Zhang L, Niederweis M
     Intricate link between siderophore secretion and drug efflux in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2023 Sep 7:e0162922. doi: 10.1128/aac.01629.
     PubMed     Abstract available
     
     
     
137. HENAO-MARTINEZ AF, Chastain DB, Thompson GR 3rd
     Treatment pathways, switches, and inappropriate treatment during invasive pulmonary aspergillosis: real-world experiences from a global research network study.
     Antimicrob Agents Chemother. 2023 Sep 6:e0072123. doi: 10.1128/aac.00721.
     PubMed     Abstract available
     
     
     
138. GIULIERI SG
     Case Commentary: The hidden side of oxacillin resistance in Staphylococcus aureus.
     Antimicrob Agents Chemother. 2023 Sep 1:e0071623. doi: 10.1128/aac.00716.
     PubMed     Abstract available
     
     
     August 2023
139. ARCARI G, Polani R, Santilli S, Capitani V, et al
     Multiplicity of bla(KPC) Genes and pKpQIL Plasmid Plasticity in the Development of Ceftazidime-Avibactam and Meropenem Coresistance in Klebsiella pneumoniae Sequence Type 307.
     Antimicrob Agents Chemother. 2023;67:e0036823.
     PubMed     Abstract available
     
     
     
140. TAIT JR, Harper M, Cortes-Lara S, Rogers KE, et al
     Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
     Antimicrob Agents Chemother. 2023;67:e0041423.
     PubMed     Abstract available
     
     
     
141. ALMANGOUR TA, Ghonem L, Alassiri D, Aljurbua A, et al
     Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.
     Antimicrob Agents Chemother. 2023;67:e0040523.
     PubMed     Abstract available
     
     
     
142. EGGE SL, Lewis JS 2nd, Hakki M
     Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-beta-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Ac
     Antimicrob Agents Chemother. 2023;67:e0066323.
     PubMed     Abstract available
     
     
     
143. WALTER ND, Ernest JP, Dide-Agossou C, Bauman AA, et al
     Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses.
     Antimicrob Agents Chemother. 2023 Aug 11:e0028423. doi: 10.1128/aac.00284.
     PubMed     Abstract available
     
     
     July 2023
144. BONILLA-MORENO M, Torrecillas M, Laporte-Amargos J, Gonzalez-Diaz A, et al
     Development of Meropenem Resistance in a Multidrug-Resistant Campylobacter coli Strain Causing Recurrent Bacteremia in a Hematological Malignancy Patient.
     Antimicrob Agents Chemother. 2023;67:e0027223.
     PubMed     Abstract available
     
     
     
145. TIRLANGI PK, Wanve BS, Dubbudu RR, Yadav BS, et al
     Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-beta-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukem
     Antimicrob Agents Chemother. 2023;67:e0050023.
     PubMed     Abstract available
     
     
     
146. WANGCHINDA W, Pogue JM
     Case Commentary: When Voldemort Meets Sauron: Treatment Considerations for Emerging Dual-Carbapenemase-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
     Antimicrob Agents Chemother. 2023;67:e0047523.
     PubMed     Abstract available
     
     
     
147. WANG X, Liu T, Lv X, Sun N, et al
     A Potential Nontraditional Approach To Combat tmexCD1-toprJ1-Mediated Tigecycline Resistance: Melatonin as a Synergistic Adjuvant of Tigecycline.
     Antimicrob Agents Chemother. 2023;67:e0004723.
     PubMed     Abstract available
     
     
     
148. VAN N, Degefu YN, Leus PA, Larkins-Ford J, et al
     Novel Synergies and Isolate Specificities in the Drug Interaction Landscape of Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2023;67:e0009023.
     PubMed     Abstract available
     
     
     
149. ZHANG Y, Liu X, Wen H, Cheng Z, et al
     Anti-Biofilm Enzymes-Assisted Antibiotic Therapy against Burn Wound Infection by Pseudomonas aeruginosa.
     Antimicrob Agents Chemother. 2023;67:e0030723.
     PubMed     Abstract available
     
     
     
150. KANE Z, Cheng I, McGarrity O, Chiesa R, et al
     Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing.
     Antimicrob Agents Chemother. 2023;67:e0007723.
     PubMed     Abstract available
     
     
     
151. MORELLI MK, Kloosterboer A, Fulton SA, Furin J, et al
     Investigating and Treating a Corneal Ulcer Due to Extensively Drug-Resistant Pseudomonas aeruginosa.
     Antimicrob Agents Chemother. 2023;67:e0027723.
     PubMed     Abstract available
     
     
     
152. SCOTT NE, Edwin Erayil S, Kline SE, Selmecki A, et al
     Rapid Evolution of Multidrug Resistance in a Candida lusitaniae Infection during Micafungin Monotherapy.
     Antimicrob Agents Chemother. 2023 Jul 10:e0054323. doi: 10.1128/aac.00543.
     PubMed     Abstract available
     
     
     
153. ZHU G, Chen S, Zhang Y, Lu L, et al
     Mitochondrial Membrane-Associated Protein Mba1 Confers Antifungal Resistance by Affecting the Production of Reactive Oxygen Species in Aspergillus fumigatus.
     Antimicrob Agents Chemother. 2023 Jul 10:e0022523. doi: 10.1128/aac.00225.
     PubMed     Abstract available
     
     
     
154. GINGRAS H, Peillard-Fiorente F, Godin C, Patron K, et al
     New Resistance Mutations Linked to Decreased Susceptibility to Solithromycin in Streptococcus pneumoniae Revealed by Chemogenomic Screens.
     Antimicrob Agents Chemother. 2023 Jul 6:e0039523. doi: 10.1128/aac.00395.
     PubMed     Abstract available
     
     
     June 2023
155. METZNER K, O'Meara MJ, Halligan B, Wotring JW, et al
     Imaging-Based Screening Identifies Modulators of the eIF3 Translation Initiation Factor Complex in Candida albicans.
     Antimicrob Agents Chemother. 2023 Jun 29:e0050323. doi: 10.1128/aac.00503.
     PubMed     Abstract available
     
     
     
156. HELFER VE, Dias BB, Lock GA, Tomaszewski CA, et al
     Population Pharmacokinetic Modeling of Free Plasma and Free Brain Concentrations of Ceftaroline in Healthy and Methicillin-Resistant Staphylococcus aureus-Infected Wistar Rats.
     Antimicrob Agents Chemother. 2023 Jun 27:e0038223. doi: 10.1128/aac.00382.
     PubMed     Abstract available
     
     
     
157. ALI AM, Radtke KK, Hesseling AC, Winckler J, et al
     QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
     Antimicrob Agents Chemother. 2023 Jun 26:e0144822. doi: 10.1128/aac.01448.
     PubMed     Abstract available
     
     
     
158. GRIES R, Dal Molin M, Chhen J, van Gumpel E, et al
     Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome bc(1) Complex.
     Antimicrob Agents Chemother. 2023 Jun 26:e0025123. doi: 10.1128/aac.00251.
     PubMed     Abstract available
     
     
     
159. SATLIN MJ, Simner PJ, Slover CM, Yamano Y, et al
     Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program.
     Antimicrob Agents Chemother. 2023 Jun 22:e0019423. doi: 10.1128/aac.00194.
     PubMed     Abstract available
     
     
     
160. HESS KA, Kooda K, Shirley JD, Schuetz AN, et al
     Failure of mecA/mecC PCR Testing to Accurately Predict Oxacillin Resistance in a Patient with Staphylococcus aureus Infective Endocarditis.
     Antimicrob Agents Chemother. 2023 Jun 21:e0043723. doi: 10.1128/aac.00437.
     PubMed     Abstract available
     
     
     
161. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
     Erratum for van der Laan et al., "Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis".
     Antimicrob Agents Chemother. 2023 Jun 20:e0072023. doi: 10.1128/aac.00720.
     PubMed    
     
     
     
162. LIU Y, Ma L, Cheng J, Su J, et al
     Effects of Omeprazole on Recurrent Clostridioides difficile Infection Caused by ST81 Strains and Their Potential Mechanisms.
     Antimicrob Agents Chemother. 2023;67:e0022123.
     PubMed     Abstract available
     
     
     
163. KIM HH, Kim S, Kim MA, Jung CH, et al
     Stratification of Nontuberculous Mycobacterial Disease Risk in Type 2 Diabetes Based on Metformin Use: a Population-Based Cohort Study in South Korea.
     Antimicrob Agents Chemother. 2023;67:e0167522.
     PubMed     Abstract available
     
     
     
164. NGUYEN TQ, Heo BE, Hanh BTB, Jeon S, et al
     DS86760016, a Leucyl-tRNA Synthetase Inhibitor, Is Active against Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2023;67:e0156722.
     PubMed     Abstract available
     
     
     
165. WANG L, Zhang X, Zhou X, Bi Y, et al
     Insertion of ISPa1635 in ISCR1 Creates a Hybrid Promoter for bla(PER-1) Resulting in Resistance to Novel beta-lactam/beta-lactamase Inhibitor Combinations and Cefiderocol.
     Antimicrob Agents Chemother. 2023;67:e0013523.
     PubMed     Abstract available
     
     
     
166. QIN Y, Wang J, Lv Q, Han B, et al
     Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review.
     Antimicrob Agents Chemother. 2023;67:e0000323.
     PubMed     Abstract available
     
     
     
167. BIDAUD AL, Moreno-Sabater A, Normand AC, Cremer G, et al
     Evaluation of Gradient Concentration Strips for Detection of Terbinafine Resistance in Trichophyton spp.
     Antimicrob Agents Chemother. 2023;67:e0171622.
     PubMed     Abstract available
     
     
     
168. ZHOU Y, Meng X, Chen F, Xiong M, et al
     Newly Discovered Antimicrobial Peptide Scyampcin(44-63) from Scylla paramamosain Exhibits a Multitargeted Candidacidal Mechanism In Vitro and Is Effective in a Murine Model of Vaginal Candidiasis.
     Antimicrob Agents Chemother. 2023;67:e0002223.
     PubMed     Abstract available
     
     
     
169. FUJIWARA K, Aono A, Asami T, Morimoto K, et al
     In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2023;67:e0157922.
     PubMed     Abstract available
     
     
     
170. HURST-HESS K, Walz A, Yang Y, McGuirk H, et al
     Intrapulmonary Treatment with Mycobacteriophage LysB Rapidly Reduces Mycobacterium abscessus Burden.
     Antimicrob Agents Chemother. 2023;67:e0016223.
     PubMed     Abstract available
     
     
     
171. CHANG YS, Li SY, Pertinez H, Betoudji F, et al
     Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy.
     Antimicrob Agents Chemother. 2023 Jun 14:e0048123. doi: 10.1128/aac.00481.
     PubMed     Abstract available
     
     
     
172. TSUI CK, Ben Abid F, Al Ismail K, McElheny CL, et al
     Genomic Epidemiology of Carbapenem-Resistant Klebsiella in Qatar: Emergence and Dissemination of Hypervirulent Klebsiella pneumoniae Sequence Type 383 Strains.
     Antimicrob Agents Chemother. 2023 Jun 13:e0003023. doi: 10.1128/aac.00030.
     PubMed     Abstract available
     
     
     May 2023
173. XU J, Li D, Shi J, Wang B, et al
     Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis.
     Antimicrob Agents Chemother. 2023 May 31:e0153222. doi: 10.1128/aac.01532.
     PubMed     Abstract available
     
     
     
174. NELSON-RIGG R, Fagan SP, Jaremko WJ, Pata JD, et al
     Pre-Steady-State Kinetic Characterization of an Antibiotic-Resistant Mutant of Staphylococcus aureus DNA Polymerase PolC.
     Antimicrob Agents Chemother. 2023 May 24:e0157122. doi: 10.1128/aac.01571.
     PubMed     Abstract available
     
     
     
175. MORRISETTE T, Stamper KC, Lev KL, Kebriaei R, et al
     Evaluation of Omadacycline Alone and in Combination with Rifampin against Staphylococcus aureus and Staphylococcus epidermidis in an In Vitro Pharmacokinetic/Pharmacodynamic Biofilm Model.
     Antimicrob Agents Chemother. 2023 May 24:e0131722. doi: 10.1128/aac.01317.
     PubMed     Abstract available
     
     
     
176. KORDALEWSKA M, Cancino-Prado G, Nobrega de Almeida Junior J, Brasil Brandao I, et al
     Novel Non-Hot Spot Modification in Fks1 of Candida auris Confers Echinocandin Resistance.
     Antimicrob Agents Chemother. 2023 May 24:e0042323. doi: 10.1128/aac.00423.
     PubMed     Abstract available
     
     
     
177. DAWSON R, Diacon AH, Narunsky K, De Jager VR, et al
     Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832.
     Antimicrob Agents Chemother. 2023 May 23:e0147722. doi: 10.1128/aac.01477.
     PubMed     Abstract available
     
     
     
178. JAKIELASZEK C, Hilliard JJ, Mannino F, Hossain M, et al
     Efficacy of Intravenously Administered Gepotidacin in Cynomolgus Macaques following a Francisella tularensis Inhalational Challenge.
     Antimicrob Agents Chemother. 2023;67:e0138122.
     PubMed     Abstract available
     
     
     
179. MASON CS, Avis T, Hu C, Nagalingam N, et al
     The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic.
     Antimicrob Agents Chemother. 2023;67:e0156322.
     PubMed     Abstract available
     
     
     
180. HU X, Dong R, Huang S, Zeng Y, et al
     CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.
     Antimicrob Agents Chemother. 2023;67:e0170422.
     PubMed     Abstract available
     
     
     
181. KOCER K, Boudour-Halil D, Chanthalangsy Q, Sahr A, et al
     Genomic Modification of TonB and Emergence of Small-Colony Phenotype in VIM- and NDM-Producing Escherichia coli following Cefiderocol Exposure In Vitro.
     Antimicrob Agents Chemother. 2023;67:e0011823.
     PubMed     Abstract available
     
     
     
182. YETMAR ZA, Chesdachai S, Lahr BD, Challener DW, et al
     Comparison of Oral and Intravenous Definitive Antibiotic Therapy for Beta-Hemolytic Streptococcus Species Bloodstream Infections from Soft Tissue Sources: a Propensity Score-Matched Analysis.
     Antimicrob Agents Chemother. 2023 May 16:e0012023. doi: 10.1128/aac.00120.
     PubMed     Abstract available
     
     
     
183. XU L, Henriksen C, Mebus V, Guerillot R, et al
     A Clinically Selected Staphylococcus aureus clpP Mutant Survives Daptomycin Treatment by Reducing Binding of the Antibiotic and Adapting a Rod-Shaped Morphology.
     Antimicrob Agents Chemother. 2023 May 15:e0032823. doi: 10.1128/aac.00328.
     PubMed     Abstract available
     
     
     
184. JOHN LLH, Thomson DD, Bicanic T, Hoenigl M, et al
     Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro.
     Antimicrob Agents Chemother. 2023 May 10:e0164522. doi: 10.1128/aac.01645.
     PubMed     Abstract available
     
     
     
185. SINGH NV, Singh KV, Dinh AQ, Arias CA, et al
     Colocalization of Linezolid Resistance (cfr) and Virulence Factors Cytolysin and Hemolysin (cln and hln) on a Plasmid in Enterococcus faecalis.
     Antimicrob Agents Chemother. 2023 May 10:e0025923. doi: 10.1128/aac.00259.
     PubMed    
     
     
     
186. MATHIYAZAKAN V, Wong CF, Harikishore A, Pethe K, et al
     Cryo-Electron Microscopy Structure of the Mycobacterium tuberculosis Cytochrome bcc:aa(3) Supercomplex and a Novel Inhibitor Targeting Subunit Cytochrome cI.
     Antimicrob Agents Chemother. 2023 May 9:e0153122. doi: 10.1128/aac.01531.
     PubMed     Abstract available
     
     
     
187. DAFFINEE KE, Piehl EC, Bleick C, LaPlante KL, et al
     Eradication of Staphylococcus epidermidis within Biofilms: Comparison of Systemic versus Supratherapeutic Concentrations of Antibiotics.
     Antimicrob Agents Chemother. 2023 May 8:e0010823. doi: 10.1128/aac.00108.
     PubMed     Abstract available
     
     
     
188. LEE JR, Satlin MJ
     Case Commentary: Unlocking the Potential of Bacteriophage to Prevent Recurrent Urinary Tract Infections after Kidney Transplantation.
     Antimicrob Agents Chemother. 2023 May 8:e0044923. doi: 10.1128/aac.00449.
     PubMed     Abstract available
     
     
     April 2023
189. STONE MC, Mychack A, Coe KA, Walker S, et al
     Combining Signal Peptidase and Lipoprotein Processing Inhibitors Overcomes Ayr Resistance in Staphylococcus aureus.
     Antimicrob Agents Chemother. 2023 Apr 25:e0011523. doi: 10.1128/aac.00115.
     PubMed     Abstract available
     
     
     
190. ZHU Y, Zhu L, Davies Forsman L, Paues J, et al
     Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
     Antimicrob Agents Chemother. 2023 Apr 25:e0170022. doi: 10.1128/aac.01700.
     PubMed     Abstract available
     
     
     
191. BEATTIE SR, Esan T, Zarnowski R, Eix E, et al
     Novel Keto-Alkyl-Pyridinium Antifungal Molecules Active in Models of In Vivo Candida albicans Vascular Catheter Infection and Ex Vivo Candida auris Skin Colonization.
     Antimicrob Agents Chemother. 2023 Apr 25:e0008123. doi: 10.1128/aac.00081.
     PubMed     Abstract available
     
     
     
192. SOBEL JD
     Resistance to Fluconazole of Candida albicans in Vaginal Isolates: a 10-Year Study in a Clinical Referral Center.
     Antimicrob Agents Chemother. 2023 Apr 24:e0018123. doi: 10.1128/aac.00181.
     PubMed     Abstract available
     
     
     
193. ELGAMMAL Y, Salama EA, Seleem MN
     Atazanavir Resensitizes Candida auris to Azoles.
     Antimicrob Agents Chemother. 2023 Apr 24:e0163122. doi: 10.1128/aac.01631.
     PubMed     Abstract available
     
     
     
194. WOOD GE, Kim CM, Aguila LKT, Cichewicz RH, et al
     In Vitro Susceptibility and Resistance of Mycoplasma genitalium to Nitroimidazoles.
     Antimicrob Agents Chemother. 2023;67:e0000623.
     PubMed     Abstract available
     
     
     
195. RODRIGUEZ R, Campbell-Kruger N, Gonzalez Camba J, Berude J, et al
     MarR-Dependent Transcriptional Regulation of mmpSL5 Induces Ethionamide Resistance in Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2023;67:e0135022.
     PubMed     Abstract available
     
     
     
196. HODGES MR, Ople E, Wedel P, Shaw KJ, et al
     Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.
     Antimicrob Agents Chemother. 2023;67:e0162322.
     PubMed     Abstract available
     
     
     
197. WANG C, Sun Z, Hu Y, Li D, et al
     A Novel Anti-CRISPR AcrIE9.2 Is Associated with Dissemination of bla(KPC) Plasmids in Klebsiella pneumoniae Sequence Type 15.
     Antimicrob Agents Chemother. 2023;67:e0154722.
     PubMed     Abstract available
     
     
     
198. HUANG Y, Wu Y, Cai C, Zhang R, et al
     Phenotypic and Genomic Characterization of ST133 Siderophore-Encoding Extensively Drug-Resistant Enterobacter hormaechei.
     Antimicrob Agents Chemother. 2023;67:e0173722.
     PubMed     Abstract available
     
     
     
199. NEGATU DA, Aragaw WW, Cangialosi J, Dartois V, et al
     Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections.
     Antimicrob Agents Chemother. 2023;67:e0165522.
     PubMed     Abstract available
     
     
     
200. D'ANGELO F, Rocha EPC, Rendueles O
     The Capsule Increases Susceptibility to Last-Resort Polymyxins, but Not to Other Antibiotics, in Klebsiella pneumoniae.
     Antimicrob Agents Chemother. 2023;67:e0012723.
     PubMed     Abstract available
     
     
     
201. LIU Y, Moodley M, Pasipanodya JG, Gumbo T, et al
     Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.
     Antimicrob Agents Chemother. 2023;67:e0140122.
     PubMed     Abstract available
     
     
     
202. ARMENGOL E, Kragh KN, Tolker-Nielsen T, Sierra JM, et al
     Colistin Enhances Rifampicin's Antimicrobial Action in Colistin-Resistant Pseudomonas aeruginosa Biofilms.
     Antimicrob Agents Chemother. 2023;67:e0164122.
     PubMed     Abstract available
     
     
     
203. TANG B, Yang A, Liu P, Wang Z, et al
     Outer Membrane Vesicles Transmitting bla(NDM-1) Mediate the Emergence of Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae.
     Antimicrob Agents Chemother. 2023 Apr 13:e0144422. doi: 10.1128/aac.01444.
     PubMed     Abstract available
     
     
     
204. VAZQUEZ JA, Pappas PG, Boffard K, Paruk F, et al
     Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial.
     Antimicrob Agents Chemother. 2023 Apr 6:e0141922. doi: 10.1128/aac.01419.
     PubMed     Abstract available
     
     
     March 2023
205. KHATEB A, Gago S, Bromley M, Richardson M, et al
     Aneuploidy Is Associated with Azole Resistance in Aspergillus fumigatus.
     Antimicrob Agents Chemother. 2023 Mar 28:e0125322. doi: 10.1128/aac.01253.
     PubMed     Abstract available
     
     
     
206. ECKHARDT E, Li Y, Mamerow S, Schinkothe J, et al
     Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside Granulomas in the Guinea Pig Model.
     Antimicrob Agents Chemother. 2023 Mar 28:e0143822. doi: 10.1128/aac.01438.
     PubMed     Abstract available
     
     
     
207. HASHIMOTO Y, Suzuki M, Kobayashi S, Hirahara Y, et al
     Enterococcal Linear Plasmids Adapt to Enterococcus faecium and Spread within Multidrug-Resistant Clades.
     Antimicrob Agents Chemother. 2023 Mar 28:e0161922. doi: 10.1128/aac.01619.
     PubMed     Abstract available
     
     
     
208. LI D, Ge Y, Wang N, Shi Y, et al
     Identification and Characterization of a Novel Major Facilitator Superfamily Efflux Pump, SA09310, Mediating Tetracycline Resistance in Staphylococcus aureus.
     Antimicrob Agents Chemother. 2023 Mar 23:e0169622. doi: 10.1128/aac.01696.
     PubMed     Abstract available
     
     
     
209. BHAVNANI SM, Hammel JP, Lakota EA, Trang M, et al
     Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
     Antimicrob Agents Chemother. 2023 Mar 22:e0221321. doi: 10.1128/aac.02213.
     PubMed     Abstract available
     
     
     
210. SLARVE M, Reyna Z, Burk E, Ruiz-Delgado J, et al
     Therapeutic, Humanized Monoclonal Antibody Exhibits Broad Binding and Protective Efficacy against Acinetobacter baumannii.
     Antimicrob Agents Chemother. 2023;67:e0008623.
     PubMed     Abstract available
     
     
     
211. HALLAL FERREIRA RARO O, Nordmann P, Dominguez Pino M, Findlay J, et al
     Emergence of Carbapenemase-Producing Hypervirulent Klebsiella pneumoniae in Switzerland.
     Antimicrob Agents Chemother. 2023;67:e0142422.
     PubMed     Abstract available
     
     
     
212. DE JESUS DFF, De Freitas ALD, De Oliveira IM, De Almeida LC, et al
     Organoselenium Has a Potent Fungicidal Effect on Cryptococcus neoformans and Inhibits the Virulence Factors.
     Antimicrob Agents Chemother. 2023;67:e0075922.
     PubMed     Abstract available
     
     
     
213. ZHANG P, Hu H, Shi Q, Sun L, et al
     The Effect of beta-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.
     Antimicrob Agents Chemother. 2023;67:e0127922.
     PubMed     Abstract available
     
     
     
214. HIRAYAMA T, Miyazaki T, Sumiyoshi M, Ito Y, et al
     Echinocandin Resistance in Candida auris Occurs in the Murine Gastrointestinal Tract Due to FKS1 Mutations.
     Antimicrob Agents Chemother. 2023 Mar 15:e0124322. doi: 10.1128/aac.01243.
     PubMed     Abstract available
     
     
     
215. LI SY, Converse PJ, Betoudji F, Lee J, et al
     Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
     Antimicrob Agents Chemother. 2023 Mar 15:e0003523. doi: 10.1128/aac.00035.
     PubMed     Abstract available
     
     
     
216. ISMAIL N, Dippenaar A, Warren RM, Peters RPH, et al
     Emergence of Canonical and Noncanonical Genomic Variants following In Vitro Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine.
     Antimicrob Agents Chemother. 2023 Mar 9:e0136822. doi: 10.1128/aac.01368.
     PubMed     Abstract available
     
     
     
217. IMBERT S, Normand AC, Costa D, Gabriel F, et al
     Multicentric Analysis of the Species Distribution and Antifungal Susceptibility of Clinical Isolates from Aspergillus Section Circumdati.
     Antimicrob Agents Chemother. 2023 Mar 9:e0146222. doi: 10.1128/aac.01462.
     PubMed     Abstract available
     
     
     
218. CABELLOS C, Guillem L, Pelegrin I, Tubau F, et al
     Reply to Le Turnier et al., "Empirical Treatment in Acute Bacterial Meningitis: a Plea for High Doses of Cefotaxime or Ceftriaxone".
     Antimicrob Agents Chemother. 2023 Mar 7:e0005023. doi: 10.1128/aac.00050.
     PubMed    
     
     
     
219. LE TURNIER P, Tattevin P, Varon E, Duval X, et al
     Empirical Treatment in Acute Bacterial Meningitis: a Plea for High Doses of Cefotaxime or Ceftriaxone.
     Antimicrob Agents Chemother. 2023 Mar 7:e0001223. doi: 10.1128/aac.00012.
     PubMed    
     
     
     
220. MISHRA NN, Abdelhady W, Elsayed AM, Lapitan C, et al
     Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis-oralis Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resist
     Antimicrob Agents Chemother. 2023 Mar 6:e0147222. doi: 10.1128/aac.01472.
     PubMed     Abstract available
     
     
     
221. ARENDS SJR, Butler D, Scangarella-Oman N, Castanheira M, et al
     Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020).
     Antimicrob Agents Chemother. 2023 Mar 6:e0152522. doi: 10.1128/aac.01525.
     PubMed     Abstract available
     
     
     February 2023
222. PRESENTE S, Bonnal C, Normand AC, Gaudonnet Y, et al
     Hospital Clonal Outbreak of Fluconazole-Resistant Candida parapsilosis Harboring the Y132F ERG11p Substitution in a French Intensive Care Unit.
     Antimicrob Agents Chemother. 2023 Feb 28:e0113022. doi: 10.1128/aac.01130.
     PubMed     Abstract available
     
     
     
223. LOHSEN S, Stephens DS
     Inducible Mega-Mediated Macrolide Resistance Confers Heteroresistance in Streptococcus pneumoniae.
     Antimicrob Agents Chemother. 2023 Feb 27:e0131922. doi: 10.1128/aac.01319.
     PubMed     Abstract available
     
     
     
224. ABDELGAWAD N, Tshavhungwe MP, Rohlwink U, McIlleron H, et al
     Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis.
     Antimicrob Agents Chemother. 2023 Feb 23:e0147422. doi: 10.1128/aac.01474.
     PubMed     Abstract available
     
     
     
225. TASCINI C, Antonelli A, Pini M, De Vivo S, et al
     Infective Endocarditis Associated with Implantable Cardiac Device by Metallo-beta-Lactamase-Producing Pseudomonas aeruginosa, Successfully Treated with Source Control and Cefiderocol Plus Imipenem.
     Antimicrob Agents Chemother. 2023 Feb 23:e0131322. doi: 10.1128/aac.01313.
     PubMed    
     
     
     
226. LEDGER EVK, Lau K, Tate EW, Edwards AM, et al
     XerC Is Required for the Repair of Antibiotic- and Immune-Mediated DNA Damage in Staphylococcus aureus.
     Antimicrob Agents Chemother. 2023 Feb 21:e0120622. doi: 10.1128/aac.01206.
     PubMed     Abstract available
     
     
     
227. CABOT G, Kim K, Mark BL, Oliver A, et al
     Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa.
     Antimicrob Agents Chemother. 2023;67:e0140922.
     PubMed     Abstract available
     
     
     
228. NEGATU DA, Gonzalez Del Rio R, Cacho-Izquierdo M, Barros-Aguirre D, et al
     Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.
     Antimicrob Agents Chemother. 2023;67:e0145922.
     PubMed     Abstract available
     
     
     
229. GARCIA A, Huh EY, Lee SC
     Serine/Threonine Phosphatase Calcineurin Orchestrates the Intrinsic Resistance to Micafungin in the Human-Pathogenic Fungus Mucor circinelloides.
     Antimicrob Agents Chemother. 2023;67:e0068622.
     PubMed     Abstract available
     
     
     
230. KUNKEL M, Doyle-Eisele M, Kuehl P, Rotermund K, et al
     Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection.
     Antimicrob Agents Chemother. 2023;67:e0114422.
     PubMed     Abstract available
     
     
     
231. LONG J, Zhang J, Xi Y, Zhao J, et al
     Genomic Insights into CRISPR-Harboring Plasmids in the Klebsiella Genus: Distribution, Backbone Structures, Antibiotic Resistance, and Virulence Determinant Profiles.
     Antimicrob Agents Chemother. 2023 Feb 15:e0118922. doi: 10.1128/aac.01189.
     PubMed     Abstract available
     
     
     
232. ALMEIDA DV, Converse PJ, Nuermberger EL
     Mutations in Rv0678 Reduce Susceptibility of Mycobacterium tuberculosis to the DprE1 Inhibitor TBA-7371.
     Antimicrob Agents Chemother. 2023 Feb 14:e0005223. doi: 10.1128/aac.00052.
     PubMed    
     
     
     
233. BONN CM, Rafiqullah IM, Crawford JA, Qian YM, et al
     Repeated Emergence of Variant TetR Family Regulator, FarR, and Increased Resistance to Antimicrobial Unsaturated Fatty Acid among Clonal Complex 5 Methicillin-Resistant Staphylococcus aureus.
     Antimicrob Agents Chemother. 2023 Feb 6:e0074922. doi: 10.1128/aac.00749.
     PubMed     Abstract available
     
     
     
234. CHIREHWA MT, Resendiz-Galvan JE, Court R, De Kock M, et al
     Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
     Antimicrob Agents Chemother. 2023 Feb 6:e0142622. doi: 10.1128/aac.01426.
     PubMed     Abstract available
     
     
     January 2023
235. CUSUMANO JA, Daffinee KE, Ugalde-Silva P, Peti W, et al
     Penicillin-Binding Proteins and Alternative Dual-Beta-Lactam Combinations for Serious Enterococcus faecalis Infections with Elevated Penicillin MICs.
     Antimicrob Agents Chemother. 2023 Jan 31:e0087122. doi: 10.1128/aac.00871.
     PubMed     Abstract available
     
     
     
236. JIMENEZ-TORO I, Rodriguez CA, Zuluaga AF, Otalvaro JD, et al
     Pharmacokinetic/Pharmacodynamic Index Linked to In Vivo Efficacy of the Ampicillin-Ceftriaxone Combination against Enterococcus faecalis.
     Antimicrob Agents Chemother. 2023 Jan 25:e0096622. doi: 10.1128/aac.00966.
     PubMed     Abstract available
     
     
     
237. SHEWELL LK, Day CJ, De Bisscop X, Edwards JL, et al
     Repurposing Carbamazepine To Treat Gonococcal Infection in Women: Oral Delivery for Control of Epilepsy Generates Therapeutically Effective Levels in Vaginal Secretions.
     Antimicrob Agents Chemother. 2023;67:e0096822.
     PubMed     Abstract available
     
     
     
238. TRANG M, Hammel JP, Lakota EA, Safir MC, et al
     Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia.
     Antimicrob Agents Chemother. 2023;67:e0220121.
     PubMed    
     
     
     
239. ZEISER ET, Becka SA, LiPuma JJ, Papp-Wallace KM, et al
     Activity of ETX0462 toward Some Burkholderia spp.
     Antimicrob Agents Chemother. 2023;67:e0135222.
     PubMed     Abstract available
     
     
     
240. SHINOHARA K, Fujisawa T, Chang B, Ito Y, et al
     Frequent Transmission of Streptococcus pneumoniae Serotype 35B and 35D, Clonal Complex 558 Lineage, across Continents and the Formation of Multiple Clades in Japan.
     Antimicrob Agents Chemother. 2023 Jan 18:e0108322. doi: 10.1128/aac.01083.
     PubMed     Abstract available
     
     
     
241. LIU H, Zhu H, Fu L, Zhang W, et al
     Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.
     Antimicrob Agents Chemother. 2023 Jan 9:e0139922. doi: 10.1128/aac.01399.
     PubMed     Abstract available
     
     
     
242. REICHLEN MJ, Born SEM, Lyons MA, Rossmassler K, et al
     Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency.
     Antimicrob Agents Chemother. 2023 Jan 9:e0148322. doi: 10.1128/aac.01483.
     PubMed     Abstract available
     
     
     
243. JARRETT RT, van der Heijden Y, Shotwell MS, Chihota V, et al
     High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
     Antimicrob Agents Chemother. 2023 Jan 9:e0129722. doi: 10.1128/aac.01297.
     PubMed     Abstract available
     
     
     
244. BLANCO-DI MATTEO A, Garcia-Fernandez N, Aguinaga Perez A, Carmona-Torre F, et al
     In Vivo Effectiveness of Several Antimicrobial Locks To Eradicate Intravascular Catheter Coagulase-Negative Staphylococci Biofilms.
     Antimicrob Agents Chemother. 2023 Jan 5:e0126422. doi: 10.1128/aac.01264.
     PubMed     Abstract available
     
     
     
245. BROWN KL, Wilburn KM, Montague CR, Grigg JC, et al
     Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium tuberculosis by the Novel Drug Candidate GSK2556286.
     Antimicrob Agents Chemother. 2023 Jan 5:e0129422. doi: 10.1128/aac.01294.
     PubMed     Abstract available
     
     
     
246. ZHANG F, Li Z, Liu X, Luo G, et al
     Molecular Characteristics of an NDM-4 and OXA-181 Co-Producing K51-ST16 Carbapenem-Resistant Klebsiella pneumoniae: Study of Its Potential Dissemination Mediated by Conjugative Plasmids and Insertion Sequences.
     Antimicrob Agents Chemother. 2023 Jan 5:e0135422. doi: 10.1128/aac.01354.
     PubMed     Abstract available
     
     
     
247. MCNEIL JC, Sommer LM, Vallejo JG, Boyle M, et al
     Going Back in Time: Increasing Penicillin Susceptibility among Methicillin-Susceptible Staphylococcus aureus Osteoarticular Infections in Children.
     Antimicrob Agents Chemother. 2023 Jan 4:e0119622. doi: 10.1128/aac.01196.
     PubMed     Abstract available
     
     
     December 2022
248. SIMAR SR, Tran TT, Rydell KB, Panesso D, et al
     Multisite Detection of Tn1549-Mediated vanB Vancomycin Resistance in Multidrug-Resistant Enterococcus faecalis ST6 in Texas and Florida.
     Antimicrob Agents Chemother. 2022 Dec 21:e0128422. doi: 10.1128/aac.01284.
     PubMed     Abstract available
     
     
     
249. AHMAD MN, Garg T, Singh S, Shukla R, et al
     In Vitro and In Vivo Activity of Gepotidacin against Drug-Resistant Mycobacterial Infections.
     Antimicrob Agents Chemother. 2022;66:e0056422.
     PubMed     Abstract available
     
     
     
250. BOONSTRA JM, van der Elst KC, Zijlstra JG, van der Werf TS, et al
     Population Pharmacokinetic Model and Optimal Sampling Strategies for Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
     Antimicrob Agents Chemother. 2022;66:e0111322.
     PubMed     Abstract available
     
     
     
251. MANESH A, Devasagayam E, Bhanuprasad K, Mathew SK, et al
     Efficacy of Crushed Delayed-Release Posaconazole Tablets in Rhino-Orbito-Cerebral Mucormycosis.
     Antimicrob Agents Chemother. 2022;66:e0108522.
     PubMed     Abstract available
     
     
     
252. ZHANG J, Chen L, Gomez-Simmonds A, Yin MT, et al
     Antibiotic-Specific Risk for Community-Acquired Clostridioides difficile Infection in the United States from 2008 to 2020.
     Antimicrob Agents Chemother. 2022;66:e0112922.
     PubMed     Abstract available
     
     
     
253. PARK YE, Chong YP, Lee HJ, Shim TS, et al
     Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
     Antimicrob Agents Chemother. 2022;66:e0052822.
     PubMed     Abstract available
     
     
     
254. BONNET PL, Le Gal S, Gautier C, Hoffmann CV, et al
     Apparent Absence of Selective Pressure on Pneumocystis jirovecii Organisms in Patients with Prior Methotrexate Exposure.
     Antimicrob Agents Chemother. 2022;66:e0099022.
     PubMed     Abstract available
     
     
     
255. GEHRKE AE, Mendoza-Bertelli A, Ledo C, Gonzalez CD, et al
     Neutralization of Staphylococcus aureus Protein A Prevents Exacerbated Osteoclast Activity and Bone Loss during Osteomyelitis.
     Antimicrob Agents Chemother. 2022 Dec 19:e0114022. doi: 10.1128/aac.01140.
     PubMed     Abstract available
     
     
     
256. KIM J, Choi J, Kang H, Ahn J, et al
     Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial.
     Antimicrob Agents Chemother. 2022 Dec 12:e0112322. doi: 10.1128/aac.01123.
     PubMed     Abstract available
     
     
     
257. RHODES NJ, Rohani R, Yarnold PR, Pawlowski AE, et al
     Machine Learning To Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia.
     Antimicrob Agents Chemother. 2022 Dec 6:e0102322. doi: 10.1128/aac.01023.
     PubMed     Abstract available
     
     
     
258. MILLER S, Goy K, She R, Spellberg B, et al
     Antimicrobial Susceptibility Testing Performed in RPMI 1640 Reveals Azithromycin Efficacy against Carbapenem-Resistant Acinetobacter baumannii and Predicts In Vivo Outcomes in Galleria mellonella.
     Antimicrob Agents Chemother. 2022 Dec 5:e0132022. doi: 10.1128/aac.01320.
     PubMed     Abstract available
     
     
     November 2022
259. LIU Y, Shi J, Li L, Wu T, et al
     Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2022 Nov 30:e0053122. doi: 10.1128/aac.00531.
     PubMed     Abstract available
     
     
     
260. WONG CF, Saw WG, Basak S, Sano M, et al
     Structural Elements Involved in ATP Hydrolysis Inhibition and ATP Synthesis of Tuberculosis and Nontuberculous Mycobacterial F-ATP Synthase Decipher New Targets for Inhibitors.
     Antimicrob Agents Chemother. 2022 Nov 29:e0105622. doi: 10.1128/aac.01056.
     PubMed     Abstract available
     
     
     
261. YU XH, Hao ZH, Liu PL, Liu MM, et al
     Increased Expression of Efflux Pump norA Drives the Rapid Evolutionary Trajectory from Tolerance to Resistance against Ciprofloxacin in Staphylococcus aureus.
     Antimicrob Agents Chemother. 2022 Nov 29:e0059422. doi: 10.1128/aac.00594.
     PubMed     Abstract available
     
     
     
262. HULL RC, Wright RCT, Sayers JR, Sutton JAF, et al
     Antibiotics Limit Adaptation of Drug-Resistant Staphylococcus aureus to Hypoxia.
     Antimicrob Agents Chemother. 2022 Nov 21:e0092622. doi: 10.1128/aac.00926.
     PubMed     Abstract available
     
     
     
263. MANSJO M, Karlsson Lindsjo O, Gronfors Seeth C, Groenheit R, et al
     The ddn Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2022 Nov 21:e0102622. doi: 10.1128/aac.01026.
     PubMed     Abstract available
     
     
     
264. LYONS MA
     Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
     Antimicrob Agents Chemother. 2022 Nov 15:e0089822. doi: 10.1128/aac.00898.
     PubMed     Abstract available
     
     
     
265. NELSON M, Burton N, Nunez A, Butcher W, et al
     Efficacy of Co-Trimoxazole against Experimental Melioidosis Acquired by Different Routes of Infection.
     Antimicrob Agents Chemother. 2022;66:e0070822.
     PubMed     Abstract available
     
     
     
266. MCCOLLAM S, Lewis JS 2nd, Bubalo J, Diaz A, et al
     Pneumocystis jirovecii Pneumonia Prophylaxis with Intravenous Pentamidine in Adult Allogeneic Hematopoietic Stem Cell Transplant Patients.
     Antimicrob Agents Chemother. 2022;66:e0083322.
     PubMed     Abstract available
     
     
     
267. WINTERS CG, Basnet RM, Faasuamalie PE, Shallom SJ, et al
     Disulfiram Is Effective against Drug-Resistant Mycobacterium abscessus in a Zebrafish Embryo Infection Model.
     Antimicrob Agents Chemother. 2022;66:e0053922.
     PubMed     Abstract available
     
     
     
268. SAH SK, Bhattacharya S, Yadav A, Husain F, et al
     Multiple Genes of Candida albicans Influencing Echinocandin Susceptibility in Caspofungin-Adapted Mutants.
     Antimicrob Agents Chemother. 2022 Nov 10:e0097722. doi: 10.1128/aac.00977.
     PubMed     Abstract available
     
     
     
269. YEO HH, Shiau CW, Jao YH, Wan TW, et al
     Rapid Bactericidal Activity of SC5005 Combined with Docosahexaenoic Acid against Multidrug-Resistant Staphylococcus aureus Persisters and Biofilms.
     Antimicrob Agents Chemother. 2022 Nov 10:e0080322. doi: 10.1128/aac.00803.
     PubMed     Abstract available
     
     
     
270. SARATHY JP, Zimmerman MD, Gengenbacher M, Dartois V, et al
     Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus In Vitro.
     Antimicrob Agents Chemother. 2022 Nov 9:e0123722. doi: 10.1128/aac.01237.
     PubMed     Abstract available
     
     
     
271. DEVENTER AT, Bryson D, Shortill M, Boraston AB, et al
     Molecular Characterization of Clinical Rel Mutations and Consequences for Resistance Expression and Fitness in Staphylococcus aureus.
     Antimicrob Agents Chemother. 2022 Nov 8:e0093822. doi: 10.1128/aac.00938.
     PubMed     Abstract available
     
     
     
272. MON AS, Ei PW, Htwe MM, Nyunt MH, et al
     First Detection of Mycobacterium tuberculosis Clinical Isolates Harboring I491F Borderline Resistance rpoB Mutation in Myanmar.
     Antimicrob Agents Chemother. 2022 Nov 7:e0092522. doi: 10.1128/aac.00925.
     PubMed    
     
     
     
273. CABELLOS C, Guillem L, Pelegrin I, Tubau F, et al
     Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis: Treatment in the Real World and in Guidelines.
     Antimicrob Agents Chemother. 2022 Nov 3:e0082022. doi: 10.1128/aac.00820.
     PubMed     Abstract available
     
     
     
274. NGUYEN TQ, Hanh BTB, Jeon S, Heo BE, et al
     Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2022 Nov 2:e0044822. doi: 10.1128/aac.00448.
     PubMed     Abstract available
     
     
     October 2022
275. AN L, Tan J, Wang Y, Liu S, et al
     Synergistic Effect of the Combination of Deferoxamine and Fluconazole In Vitro and In Vivo against Fluconazole-Resistant Candida Spp.
     Antimicrob Agents Chemother. 2022 Oct 26:e0072522. doi: 10.1128/aac.00725.
     PubMed     Abstract available
     
     
     
276. SINGH KV, Montealegre MC, Murray BE
     Enterococcus faecium Clade Competition in the Presence of beta-Lactam Antibiotics in a Mouse GI Tract Colonization Model.
     Antimicrob Agents Chemother. 2022 Oct 18:e0090322. doi: 10.1128/aac.00903.
     PubMed     Abstract available
     
     
     
277. MCNEIL JC, Sommer LM, Vallejo JG, Hulten KG, et al
     Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation.
     Antimicrob Agents Chemother. 2022;66:e0074522.
     PubMed     Abstract available
     
     
     
278. KIM SR, Jang M, Kim SY, Kim DH, et al
     Outcomes of Short-Term Tigecycline-Containing Regimens for Mycobacterium abscessus Pulmonary Disease.
     Antimicrob Agents Chemother. 2022;66:e0077422.
     PubMed     Abstract available
     
     
     
279. PETRAITIS V, Petraitiene R, Kavaliauskas P, Naing E, et al
     Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.
     Antimicrob Agents Chemother. 2022;66:e0061822.
     PubMed     Abstract available
     
     
     
280. PHIPPS AJ, Bergmann JN, Albrecht MT, Singh VK, et al
     Model for Evaluating Antimicrobial Therapy To Prevent Life-Threatening Bacterial Infections following Exposure to a Medically Significant Radiation Dose.
     Antimicrob Agents Chemother. 2022;66:e0054622.
     PubMed     Abstract available
     
     
     
281. AL-ZUBAIDI A, Cheung CY, Cook GM, Taiaroa G, et al
     RNase HI Depletion Strongly Potentiates Cell Killing by Rifampicin in Mycobacteria.
     Antimicrob Agents Chemother. 2022;66:e0209121.
     PubMed     Abstract available
     
     
     
282. FINDLAY J, Rens C, Poirel L, Nordmann P, et al
     In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.
     Antimicrob Agents Chemother. 2022;66:e0091822.
     PubMed     Abstract available
     
     
     
283. PINCUS NB, Rosas-Lemus M, Gatesy SWM, Bertucci HK, et al
     Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family beta-Lactamase from Pseudomonas aeruginosa.
     Antimicrob Agents Chemother. 2022;66:e0098522.
     PubMed     Abstract available
     
     
     
284. MON KKZ, Si Z, Chan-Park MB, Kenney LJ, et al
     Polyimidazolium Protects against an Invasive Clinical Isolate of Salmonella Typhimurium.
     Antimicrob Agents Chemother. 2022;66:e0059722.
     PubMed     Abstract available
     
     
     
285. KUNZ COYNE AJ, Alshaer M, Casapao AM, Venugopalan V, et al
     Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection.
     Antimicrob Agents Chemother. 2022;66:e0064622.
     PubMed     Abstract available
     
     
     
286. KIM TY, Huh HJ, Lee GY, Choi MJ, et al
     Evolution of Fluconazole Resistance Mechanisms and Clonal Types of Candida parapsilosis Isolates from a Tertiary Care Hospital in South Korea.
     Antimicrob Agents Chemother. 2022 Oct 13:e0088922. doi: 10.1128/aac.00889.
     PubMed     Abstract available
     
     
     
287. HISATSUNE J, Tanimoto K, Kohara T, Myoken Y, et al
     First Isolation of Vancomycin-Resistant Enterococcus faecium Carrying Plasmid-Borne vanD1.
     Antimicrob Agents Chemother. 2022 Oct 12:e0102922. doi: 10.1128/aac.01029.
     PubMed     Abstract available
     
     
     
288. PLAUNT AJ, Rose SJ, Kang JY, Chen KJ, et al
     Correction for Plaunt et al., "Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections".
     Antimicrob Agents Chemother. 2022 Oct 12:e0125622. doi: 10.1128/aac.01256.
     PubMed    
     
     
     
289. YAO S, Wei D, Tang N, Song Y, et al
     Efficient Suppression of Natural Plasmid-Borne Gene Expression in Carbapenem-Resistant Klebsiella pneumoniae Using a Compact CRISPR Interference System.
     Antimicrob Agents Chemother. 2022 Oct 12:e0089022. doi: 10.1128/aac.00890.
     PubMed     Abstract available
     
     
     
290. PI R, Chen X, Meng J, Liu Q, et al
     Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2022 Oct 3:e0103422. doi: 10.1128/aac.01034.
     PubMed     Abstract available
     
     
     
291. RAMBACH G, Striednig B, Neurauter M, Hermann M, et al
     Indications that the Antimycotic Drug Amphotericin B Enhances the Impact of Platelets on Aspergillus.
     Antimicrob Agents Chemother. 2022 Oct 3:e0068122. doi: 10.1128/aac.00681.
     PubMed     Abstract available
     
     
     September 2022
292. MENDES RE, Hubler C, Kimbrough JH, Kantro V, et al
     In Vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020).
     Antimicrob Agents Chemother. 2022 Sep 28:e0121422. doi: 10.1128/aac.01214.
     PubMed     Abstract available
     
     
     
293. YAMADA W, Kim S, Almoslem M, Kim S, et al
     Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype.
     Antimicrob Agents Chemother. 2022 Sep 27:e0069522. doi: 10.1128/aac.00695.
     PubMed     Abstract available
     
     
     
294. COX GW, Avery BP, Parmley EJ, Irwin RJ, et al
     A One Health Genomic Investigation of Gentamicin Resistance in Escherichia coli from Human and Chicken Sources in Canada, 2014 to 2017.
     Antimicrob Agents Chemother. 2022 Sep 27:e0067722. doi: 10.1128/aac.00677.
     PubMed     Abstract available
     
     
     
295. CUSUMANO JA, Daffinee KE, Piehl EC, Garcia-Solache M, et al
     Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an In Vitro Pharmacodynamic Model Using Humanized Dosing Simulations.
     Antimicrob Agents Chemother. 2022 Sep 26:e0042622. doi: 10.1128/aac.00426.
     PubMed     Abstract available
     
     
     
296. RUEGSEGGER L, Xiao J, Naziripour A, Kanumuambidi T, et al
     Multidrug-Resistant Gram-Negative Bacteria in Burn Patients.
     Antimicrob Agents Chemother. 2022;66:e0068822.
     PubMed     Abstract available
     
     
     
297. LIU F, Gao J, Gao M, Liu Y, et al
     Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
     Antimicrob Agents Chemother. 2022;66:e0203321.
     PubMed     Abstract available
     
     
     
298. MADANI A, Negatu DA, El Marrouni A, Miller RR, et al
     Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2022;66:e0066922.
     PubMed     Abstract available
     
     
     
299. KARLOWSKY JA, Hackel MA, McLeod SM, Miller AA, et al
     In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021.
     Antimicrob Agents Chemother. 2022;66:e0078122.
     PubMed     Abstract available
     
     
     
300. HOBSON CA, Pierrat G, Tenaillon O, Bonacorsi S, et al
     Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
     Antimicrob Agents Chemother. 2022;66:e0044722.
     PubMed     Abstract available
     
     
     
301. JEN FE, Edwards JL, El-Deeb IM, Walker MJ, et al
     Repurposing the Ionophore, PBT2, for Treatment of Multidrug-Resistant Neisseria gonorrhoeae Infections.
     Antimicrob Agents Chemother. 2022;66:e0231821.
     PubMed     Abstract available
     
     
     
302. PARK S, Russo R, Westfall L, Shrestha R, et al
     A Novel Oral GyrB/ParE Dual Binding Inhibitor Effective against Multidrug-Resistant Neisseria gonorrhoeae and Other High-Threat Pathogens.
     Antimicrob Agents Chemother. 2022;66:e0041422.
     PubMed     Abstract available
     
     
     
303. LEWIS JS 2ND, Wiederhold NP, Hakki M, Thompson GR 3rd, et al
     New Perspectives on Antimicrobial Agents: Isavuconazole.
     Antimicrob Agents Chemother. 2022;66:e0017722.
     PubMed     Abstract available
     
     
     
304. WU W, He S, Li A, Guo Q, et al
     A Novel Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Expresses Anti-Mycobacterium abscessus Activity In Vitro and In Vivo.
     Antimicrob Agents Chemother. 2022;66:e0060122.
     PubMed     Abstract available
     
     
     
305. CHAE G, Park YE, Chong YP, Lee HJ, et al
     Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.
     Antimicrob Agents Chemother. 2022;66:e0226121.
     PubMed     Abstract available
     
     
     
306. BROWN-ELLIOTT BA, Wallace RJ Jr
     In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria.
     Antimicrob Agents Chemother. 2022;66:e0068922.
     PubMed     Abstract available
     
     
     
307. LUTERBACH CL, Qiu H, Hanafin PO, Sharma R, et al
     A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
     Antimicrob Agents Chemother. 2022 Sep 20:e0059122. doi: 10.1128/aac.00591.
     PubMed     Abstract available
     
     
     
308. ZOU J, Chen S, Rao W, Fu L, et al
     Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China.
     Antimicrob Agents Chemother. 2022 Sep 15:e0081122. doi: 10.1128/aac.00811.
     PubMed     Abstract available
     
     
     
309. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
     Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.
     Antimicrob Agents Chemother. 2022 Sep 7:e0227721. doi: 10.1128/aac.02277.
     PubMed     Abstract available
     
     
     
310. STANTON RA, Campbell D, McAllister GA, Breaker E, et al
     Whole-Genome Sequencing Reveals Diversity of Carbapenem-Resistant Pseudomonas aeruginosa Collected through CDC's Emerging Infections Program, United States, 2016-2018.
     Antimicrob Agents Chemother. 2022 Sep 6:e0049622. doi: 10.1128/aac.00496.
     PubMed     Abstract available
     
     
     August 2022
311. KIM LH, Kang SM, Whang J, Kwon KW, et al
     Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection.
     Antimicrob Agents Chemother. 2022 Aug 30:e0076222. doi: 10.1128/aac.00762.
     PubMed     Abstract available
     
     
     
312. SHEE S, Singh S, Tripathi A, Thakur C, et al
     Moxifloxacin-Mediated Killing of Mycobacterium tuberculosis Involves Respiratory Downshift, Reductive Stress, and Accumulation of Reactive Oxygen Species.
     Antimicrob Agents Chemother. 2022 Aug 17:e0059222. doi: 10.1128/aac.00592.
     PubMed     Abstract available
     
     
     
313. SARIS A, Qin W, van Linge CCA, Reijnders TDY, et al
     The Azithromycin Pro-Drug CSY5669 Boosts Bacterial Killing While Attenuating Lung Inflammation Associated with Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus.
     Antimicrob Agents Chemother. 2022 Aug 16:e0229821. doi: 10.1128/aac.02298.
     PubMed     Abstract available
     
     
     
314. POIREL L, Ortiz de la Rosa JM, Sakaoglu Z, Kusaksizoglu A, et al
     NDM-35-Producing ST167 Escherichia coli Highly Resistant to beta-Lactams Including Cefiderocol.
     Antimicrob Agents Chemother. 2022;66:e0031122.
     PubMed     Abstract available
     
     
     
315. MENON ND, Penziner S, Montano ET, Zurich R, et al
     Increased Innate Immune Susceptibility in Hyperpigmented Bacteriophage-Resistant Mutants of Pseudomonas aeruginosa.
     Antimicrob Agents Chemother. 2022;66:e0023922.
     PubMed     Abstract available
     
     
     
316. MCPHERSON J, Hu C, Begum K, Wang W, et al
     Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection.
     Antimicrob Agents Chemother. 2022;66:e0224421.
     PubMed     Abstract available
     
     
     
317. OSTAPSKA H, Raju D, Corsini R, Lehoux M, et al
     Preclinical Evaluation of Recombinant Microbial Glycoside Hydrolases as Antibiofilm Agents in Acute Pulmonary Pseudomonas aeruginosa Infection.
     Antimicrob Agents Chemother. 2022;66:e0005222.
     PubMed     Abstract available
     
     
     
318. COSTA DVS, Pham NVS, Hays RA, Bolick DT, et al
     Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
     Antimicrob Agents Chemother. 2022;66:e0048922.
     PubMed     Abstract available
     
     
     
319. WIEDERHOLD NP, Patterson TF, Rebholz S, Boal CWC, et al
     The Antifungal and Anti-Pneumocystis Activities of the Novel Compound A3IS (Mycosinate).
     Antimicrob Agents Chemother. 2022;66:e0052122.
     PubMed     Abstract available
     
     
     
320. CHOCHUA S, Metcalf B, Li Z, Mathis S, et al
     Invasive Group A Streptococcal Penicillin Binding Protein 2x Variants Associated with Reduced Susceptibility to beta-Lactam Antibiotics in the United States, 2015-2021.
     Antimicrob Agents Chemother. 2022 Aug 15:e0080222. doi: 10.1128/aac.00802.
     PubMed     Abstract available
     
     
     
321. GEBERETSADIK G, Inaizumi A, Nishiyama A, Yamaguchi T, et al
     Lysocin E Targeting Menaquinone in the Membrane of Mycobacterium tuberculosis Is a Promising Lead Compound for Antituberculosis Drugs.
     Antimicrob Agents Chemother. 2022 Aug 15:e0017122. doi: 10.1128/aac.00171.
     PubMed     Abstract available
     
     
     
322. VALCEK A, Nesporova K, Whiteway C, De Pooter T, et al
     Genomic Analysis of a Strain Collection Containing Multidrug-, Extensively Drug-, Pandrug-, and Carbapenem-Resistant Modern Clinical Isolates of Acinetobacter baumannii.
     Antimicrob Agents Chemother. 2022 Aug 15:e0089222. doi: 10.1128/aac.00892.
     PubMed     Abstract available
     
     
     
323. BRUNAUGH AD, Walz A, Warnken Z, Pearce C, et al
     Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection.
     Antimicrob Agents Chemother. 2022 Aug 9:e0018622. doi: 10.1128/aac.00186.
     PubMed     Abstract available
     
     
     
324. BARNIER JP, Saidjalolov S, Bouchet F, Mayer L, et al
     Modulation of the Specificity of Carbapenems and Diazabicyclooctanes for Selective Activity against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2022 Aug 9:e0235721. doi: 10.1128/aac.02357.
     PubMed     Abstract available
     
     
     
325. YUN HY, Chang MJ, Jung H, Chang V, et al
     Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients.
     Antimicrob Agents Chemother. 2022 Aug 8:e0189321. doi: 10.1128/aac.01893.
     PubMed     Abstract available
     
     
     
326. DING Y, Zhu H, Fu L, Zhang W, et al
     Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
     Antimicrob Agents Chemother. 2022 Aug 4:e0065822. doi: 10.1128/aac.00658.
     PubMed     Abstract available
     
     
     
327. ESCRIBANO P, Gomez A, Reigadas E, Munoz P, et al
     EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium Species and Lomentospora prolificans Showed High Agreements between Visual Inspection and Spectrophotometric Readings.
     Antimicrob Agents Chemother. 2022 Aug 4:e0084922. doi: 10.1128/aac.00849.
     PubMed     Abstract available
     
     
     
328. POULTON NC, Azadian ZA, DeJesus MA, Rock JM, et al
     Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2022 Aug 3:e0090422. doi: 10.1128/aac.00904.
     PubMed     Abstract available
     
     
     
329. COLABARDINI AC, Van Rhijn N, LaBella AL, Valero C, et al
     Aspergillus fumigatus FhdA Transcription Factor Is Important for Mitochondrial Activity and Codon Usage Regulation during the Caspofungin Paradoxical Effect.
     Antimicrob Agents Chemother. 2022 Aug 2:e0070122. doi: 10.1128/aac.00701.
     PubMed     Abstract available
     
     
     
330. EDLIND T, Katiyar S
     Intrinsically High Resistance of Candida glabrata to Hydrogen Peroxide and Its Reversal in a Fluconazole-Resistant Mutant.
     Antimicrob Agents Chemother. 2022 Aug 2:e0072122. doi: 10.1128/aac.00721.
     PubMed    
     
     
     
331. GRACIAA DS, Kipiani M, Magee MJ, Mikiashvili L, et al
     Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2022 Aug 2:e0040822. doi: 10.1128/aac.00408.
     PubMed     Abstract available
     
     
     July 2022
332. SHELTON CD, McNeil MB, Early JV, Ioerger TR, et al
     Correction for Shelton et al., "Deletion of Rv2571c Confers Resistance to Arylamide Compounds in Mycobacterium tuberculosis".
     Antimicrob Agents Chemother. 2022 Jul 25:e0096222. doi: 10.1128/aac.00962.
     PubMed    
     
     
     
333. CHANG SC, Lin LC, Lu JJ
     An lnu(A)-Carrying Multi-Resistance Plasmid Derived from Sequence Type 3 Methicillin-Resistant Staphylococcus lugdunensis May Contribute to Antimicrobial Resistance in Staphylococci.
     Antimicrob Agents Chemother. 2022 Jul 25:e0019722. doi: 10.1128/aac.00197.
     PubMed     Abstract available
     
     
     
334. HARISH E, Sarkar A, Handelman M, Abo Kandil A, et al
     Triazole Priming as an Adaptive Response and Gateway to Resistance in Aspergillus fumigatus.
     Antimicrob Agents Chemother. 2022 Jul 20:e0045822. doi: 10.1128/aac.00458.
     PubMed     Abstract available
     
     
     
335. LOPEZ-CERERO L, Stolz E, Pulido MR, Pascual A, et al
     Characterization of Extended-Spectrum beta-Lactamase-Producing Shigella sonnei in Spain: Expanding the Geographic Distribution of Sequence Type 152/CTX-M-27 Clone.
     Antimicrob Agents Chemother. 2022;66:e0033422.
     PubMed     Abstract available
     
     
     
336. DAI YY, Qin C, Huang GR, Qin YC, et al
     Linolenic Acid-Metronidazole: a Compound Relieving Drug Resistance and Inhibiting Helicobacter pylori.
     Antimicrob Agents Chemother. 2022;66:e0007322.
     PubMed     Abstract available
     
     
     
337. MADDEN GR, Petri WA Jr, Costa DVS, Warren CA, et al
     Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes.
     Antimicrob Agents Chemother. 2022;66:e0067622.
     PubMed     Abstract available
     
     
     
338. O'DONNELL JN, Lodise TP
     New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
     Antimicrob Agents Chemother. 2022;66:e0025622.
     PubMed     Abstract available
     
     
     
339. SEN T, Verma NK
     Functional Role of YnfA, an Efflux Transporter in Resistance to Antimicrobial Agents in Shigella flexneri.
     Antimicrob Agents Chemother. 2022;66:e0029322.
     PubMed     Abstract available
     
     
     
340. PARK JJ, Jung EJ, Kim JY, Seo YB, et al
     Thirty-Day Mortality Rates in Patients with Extended-Spectrum beta-Lactamase-Producing Enterobacterales Bacteremia Receiving Ertapenem versus Other Carbapenems.
     Antimicrob Agents Chemother. 2022;66:e0028722.
     PubMed     Abstract available
     
     
     
341. DESAI JV, Urban A, Swaim DZ, Colton B, et al
     Efficacy of Cochleated Amphotericin B in Mouse and Human Mucocutaneous Candidiasis.
     Antimicrob Agents Chemother. 2022;66:e0030822.
     PubMed     Abstract available
     
     
     
342. GEBREMARIAM T, Gu Y, Alkhazraji S, Youssef E, et al
     The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections.
     Antimicrob Agents Chemother. 2022;66:e0038022.
     PubMed     Abstract available
     
     
     
343. PITOUT JDD, Peirano G, Chen L, DeVinney R, et al
     Escherichia coli ST1193: Following in the Footsteps of E. coli ST131.
     Antimicrob Agents Chemother. 2022;66:e0051122.
     PubMed     Abstract available
     
     
     
344. MTSHALI S, Jacobs BA
     A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
     Antimicrob Agents Chemother. 2022 Jul 19:e0027422. doi: 10.1128/aac.00274.
     PubMed     Abstract available
     
     
     
345. DIAZ-GARCIA J, Gomez A, Alcala L, Reigadas E, et al
     Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p Substitution.
     Antimicrob Agents Chemother. 2022 Jul 19:e0071022. doi: 10.1128/aac.00710.
     PubMed     Abstract available
     
     
     
346. MEHTA K, Guo T, Wallis RS, van der Graaf PH, et al
     Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy.
     Antimicrob Agents Chemother. 2022 Jul 14:e0036622. doi: 10.1128/aac.00366.
     PubMed     Abstract available
     
     
     
347. KONG X, Wang B, Chen X, Wang L, et al
     Hinokiflavone Attenuates the Virulence of Methicillin-Resistant Staphylococcus aureus by Targeting Caseinolytic Protease P.
     Antimicrob Agents Chemother. 2022 Jul 11:e0024022. doi: 10.1128/aac.00240.
     PubMed     Abstract available
     
     
     
348. KNOLL MA, Samardzic E, Posch W, Lass-Florl C, et al
     Evaluation of Inoculum Preparation for Etest and EUCAST Broth Dilution to Detect Anidulafungin Polyresistance in Candida glabrata.
     Antimicrob Agents Chemother. 2022 Jul 11:e0016822. doi: 10.1128/aac.00168.
     PubMed     Abstract available
     
     
     
349. SOUCHE A, Kolenda C, Teoli J, Schuch R, et al
     Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections.
     Antimicrob Agents Chemother. 2022 Jul 11:e0058822. doi: 10.1128/aac.00588.
     PubMed     Abstract available
     
     
     
350. WATANABE F, Furuuchi K, Hanada K, Fujiwara K, et al
     Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection.
     Antimicrob Agents Chemother. 2022 Jul 7:e0044122. doi: 10.1128/aac.00441.
     PubMed     Abstract available
     
     
     June 2022
351. JACOBS SE, Jacobs JL, Dennis EK, Taimur S, et al
     Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.
     Antimicrob Agents Chemother. 2022 Jun 30:e0005322. doi: 10.1128/aac.00053.
     PubMed     Abstract available
     
     
     
352. HSU AJ, Tamma PD, Fisher BT
     Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.
     Antimicrob Agents Chemother. 2022 Jun 29:e0215621. doi: 10.1128/aac.02156.
     PubMed     Abstract available
     
     
     
353. BAE S, Kim ES, Kim HS, Yang E, et al
     Risk Factors of Recurrent Infection in Patients with Staphylococcus aureus Bacteremia: a Competing Risk Analysis.
     Antimicrob Agents Chemother. 2022 Jun 28:e0012622. doi: 10.1128/aac.00126.
     PubMed     Abstract available
     
     
     
354. RIVIERE E, Verboven L, Dippenaar A, Goossens S, et al
     Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with Mycobacterium tuberculosis Lineage.
     Antimicrob Agents Chemother. 2022 Jun 27:e0032222. doi: 10.1128/aac.00322.
     PubMed     Abstract available
     
     
     
355. KWIECINSKI JM, Jelani DA, Fuentes EJ, Horswill AR, et al
     Therapeutic Inhibition of Staphylococcus aureus ArlRS Two-Component Regulatory System Blocks Virulence.
     Antimicrob Agents Chemother. 2022 Jun 23:e0018722. doi: 10.1128/aac.00187.
     PubMed     Abstract available
     
     
     
356. ABOLHASSANI-CHIMEH R, Akkerman OW, Saktiawati AMI, Punt NC, et al
     Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.
     Antimicrob Agents Chemother. 2022 Jun 21:e0000322. doi: 10.1128/aac.00003.
     PubMed     Abstract available
     
     
     
357. PHILLIPS EC, Warren CA, Ma JZ, Madden GR, et al
     Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.
     Antimicrob Agents Chemother. 2022;66:e0000122.
     PubMed     Abstract available
     
     
     
358. RIMAL B, Batchelder HR, Story-Roller E, Panthi CM, et al
     T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with beta-Lactams Imipenem and Cefditoren.
     Antimicrob Agents Chemother. 2022;66:e0053622.
     PubMed     Abstract available
     
     
     
359. XIE J, Yang Q, Han X, Dong Y, et al
     Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation.
     Antimicrob Agents Chemother. 2022;66:e0009922.
     PubMed     Abstract available
     
     
     
360. WILLIAMS E, Zhang B, Chow EPF, Chea S, et al
     Inhibitory Activity of Antibacterial Mouthwashes and Antiseptic Substances against Neisseria gonorrhoeae.
     Antimicrob Agents Chemother. 2022;66:e0004222.
     PubMed     Abstract available
     
     
     
361. HUGGINS JP, Pease R, Stanly K, Workman A, et al
     Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients.
     Antimicrob Agents Chemother. 2022;66:e0028322.
     PubMed     Abstract available
     
     
     
362. TRAN TT, Gomez Villegas S, Aitken SL, Butler-Wu SM, et al
     New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.
     Antimicrob Agents Chemother. 2022;66:e0261420.
     PubMed     Abstract available
     
     
     
363. WALTER K, Kokesch-Himmelreich J, Treu A, Waldow F, et al
     Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.
     Antimicrob Agents Chemother. 2022;66:e0158821.
     PubMed     Abstract available
     
     
     
364. TONG K, Wei J, Gu H, Hu Q, et al
     Evaluation of Experimental and Clinical Efficacy on Surgical Debridement and Systemic Antibiotics Treatment for Early Knee Infection after Anterior Cruciate Ligament Reconstruction.
     Antimicrob Agents Chemother. 2022;66:e0011222.
     PubMed     Abstract available
     
     
     
365. MCCALLIN S, Menzi C, Lassen S, Daraspe J, et al
     Antibiotic Exposure Leads to Reduced Phage Susceptibility in Vancomycin Intermediate Staphylococcus aureus (VISA).
     Antimicrob Agents Chemother. 2022 Jun 16:e0224721. doi: 10.1128/aac.02247.
     PubMed     Abstract available
     
     
     
366. DOORLEY LA, Rybak JM, Berkow EL, Zhang Q, et al
     Candida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance.
     Antimicrob Agents Chemother. 2022 Jun 14:e0028922. doi: 10.1128/aac.00289.
     PubMed     Abstract available
     
     
     
367. SONG W, Wang L, Jin M, Guo X, et al
     Punicalagin, an Inhibitor of Sortase A, Is a Promising Therapeutic Drug to Combat Methicillin-Resistant Staphylococcus aureus Infections.
     Antimicrob Agents Chemother. 2022 Jun 2:e0022422. doi: 10.1128/aac.00224.
     PubMed     Abstract available
     
     
     
368. SHIVARATHRI R, Jenull S, Chauhan M, Singh A, et al
     Comparative Transcriptomics Reveal Possible Mechanisms of Amphotericin B Resistance in Candida auris.
     Antimicrob Agents Chemother. 2022 Jun 2:e0227621. doi: 10.1128/aac.02276.
     PubMed     Abstract available
     
     
     
369. SHAO Y, Chen M, Luo J, Li D, et al
     Serogroup Y Clonal Complex 23 Meningococcus in China Acquiring Penicillin Resistance from Commensal Neisseria lactamica Species.
     Antimicrob Agents Chemother. 2022 Jun 2:e0238321. doi: 10.1128/aac.02383.
     PubMed     Abstract available
     
     
     
370. ZHOU Y, Zhong Z, Hu S, Wang J, et al
     A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China.
     Antimicrob Agents Chemother. 2022 Jun 2:e0218821. doi: 10.1128/aac.02188.
     PubMed     Abstract available
     
     
     
371. CHEN M, Zhong G, Wang S, Chen P, et al
     Deletion of cox7c Results in Pan-Azole Resistance in Aspergillus fumigatus.
     Antimicrob Agents Chemother. 2022 Jun 1:e0015122. doi: 10.1128/aac.00151.
     PubMed     Abstract available
     
     
     
372. ISHIKAWA K, Uehara Y, Mori N, Mikami Y, et al
     In Vitro Activity and Clinical Efficacy of Faropenem against Third-Generation Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae.
     Antimicrob Agents Chemother. 2022 Jun 1:e0012522. doi: 10.1128/aac.00125.
     PubMed     Abstract available
     
     
     May 2022
373. NUERMBERGER EL, Martinez-Martinez MS, Sanz O, Urones B, et al
     GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.
     Antimicrob Agents Chemother. 2022 May 24:e0013222. doi: 10.1128/aac.00132.
     PubMed     Abstract available
     
     
     
374. SOBEL JD, Akins R
     Determining Susceptibility in Candida Vaginal Isolates.
     Antimicrob Agents Chemother. 2022 May 23:e0236621. doi: 10.1128/aac.02366.
     PubMed     Abstract available
     
     
     
375. KARLOWSKY JA, Lob SH, DeRyke CA, Hilbert DW, et al
     In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 202
     Antimicrob Agents Chemother. 2022;66:e0018922.
     PubMed     Abstract available
     
     
     
376. LI X, Le W, Lou X, Genco CA, et al
     In Vitro Activity of Ertapenem against Neisseria gonorrhoeae Clinical Isolates with Decreased Susceptibility or Resistance to Extended-Spectrum Cephalosporins in Nanjing, China (2013 to 2019).
     Antimicrob Agents Chemother. 2022;66:e0010922.
     PubMed     Abstract available
     
     
     
377. MURRAY GL, Bodiyabadu K, Vodstrcil LA, Machalek DA, et al
     parC Variants in Mycoplasma genitalium: Trends over Time and Association with Moxifloxacin Failure.
     Antimicrob Agents Chemother. 2022;66:e0027822.
     PubMed     Abstract available
     
     
     
378. PRASAD NK, Seiple IB, Cirz RT, Rosenberg OS, et al
     Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020.
     Antimicrob Agents Chemother. 2022;66:e0005422.
     PubMed     Abstract available
     
     
     
379. GAO W, Passarell J, Patel YT, Zhang Z, et al
     Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
     Antimicrob Agents Chemother. 2022;66:e0139921.
     PubMed     Abstract available
     
     
     
380. PAUL A, Nair RR, Jakkala K, Pradhan A, et al
     Elevated Levels of Three Reactive Oxygen Species and Fe(II) in the Antibiotic-Surviving Population of Mycobacteria Facilitate De Novo Emergence of Genetic Resisters to Antibiotics.
     Antimicrob Agents Chemother. 2022;66:e0228521.
     PubMed     Abstract available
     
     
     
381. HUJER AM, Bethel CR, Taracila MA, Marshall SH, et al
     Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant beta-Lactamases and Their Increasing Importance.
     Antimicrob Agents Chemother. 2022;66:e0179021.
     PubMed     Abstract available
     
     
     
382. SCHULTHESS B, Akdogan Kittana FN, Homke R, Sander P, et al
     In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2022;66:e0234621.
     PubMed     Abstract available
     
     
     
383. CHUA TP, Danielewski J, Bodiyabadu K, Bradshaw CS, et al
     Impact of 16S rRNA Single Nucleotide Polymorphisms on Mycoplasma genitalium Organism Load with Doxycycline Treatment.
     Antimicrob Agents Chemother. 2022;66:e0024322.
     PubMed     Abstract available
     
     
     
384. LANDLINGER C, Oberbauer V, Podpera Tisakova L, Schwebs T, et al
     Preclinical Data on the Gardnerella-Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal and Avoidance of Resistance.
     Antimicrob Agents Chemother. 2022;66:e0231921.
     PubMed     Abstract available
     
     
     
385. DESNOS-OLLIVIER M, Bretagne S, Lortholary O, Dromer F, et al
     Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.
     Antimicrob Agents Chemother. 2022;66:e0172521.
     PubMed     Abstract available
     
     
     
386. KARABA SM, Hirsch EB, Heil EL
     In a Pinch: Cefiderocol for CRAB Infections.
     Antimicrob Agents Chemother. 2022;66:e0006522.
     PubMed     Abstract available
     
     
     
387. KARABASEVIC N, Roberts JA, Stronach L, Naicker S, et al
     Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates.
     Antimicrob Agents Chemother. 2022;66:e0214021.
     PubMed     Abstract available
     
     
     
388. ERSOY SC, Manna AC, Proctor RA, Chambers HF, et al
     The NaHCO3-Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus (MRSA) Is Influenced by mecA Genotype.
     Antimicrob Agents Chemother. 2022 May 16:e0025222. doi: 10.1128/aac.00252.
     PubMed     Abstract available
     
     
     
389. SUPANDY A, Mehta HH, Tran TT, Miller WR, et al
     Evolution of Enterococcus faecium in Response to a Combination of Daptomycin and Fosfomycin Reveals Distinct and Diverse Adaptive Strategies.
     Antimicrob Agents Chemother. 2022 May 11:e0233321. doi: 10.1128/aac.02333.
     PubMed     Abstract available
     
     
     
390. FUCHS F, Aldejohann AM, Hoffmann AM, Walther G, et al
     In Vitro Activity of Nitroxoline in Antifungal-Resistant Candida Species Isolated from the Urinary Tract.
     Antimicrob Agents Chemother. 2022 May 11:e0226521. doi: 10.1128/aac.02265.
     PubMed     Abstract available
     
     
     
391. MOURAD A, Holland TL, Turner NA
     Antiplatelet Therapy in Staphylococcus aureus Bacteremia: No Time Like the Past?
     Antimicrob Agents Chemother. 2022 May 10:e0036522. doi: 10.1128/aac.00365.
     PubMed     Abstract available
     
     
     
392. CONKLE-GUTIERREZ D, Kim C, Ramirez-Busby SM, Modlin SJ, et al
     Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study.
     Antimicrob Agents Chemother. 2022 May 9:e0207521. doi: 10.1128/aac.02075.
     PubMed     Abstract available
     
     
     
393. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
     Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2022 May 4:e0226421. doi: 10.1128/aac.02264.
     PubMed     Abstract available
     
     
     April 2022
394. RAGUNATHAN P, Dick T, Gruber G
     Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1.
     Antimicrob Agents Chemother. 2022 Apr 28:e0001822. doi: 10.1128/aac.00018.
     PubMed     Abstract available
     
     
     
395. MADDEN DE, Olagoke O, Baird T, Neill J, et al
     Express Yourself: Quantitative Real-Time PCR Assays for Rapid Chromosomal Antimicrobial Resistance Detection in Pseudomonas aeruginosa.
     Antimicrob Agents Chemother. 2022 Apr 25:e0020422. doi: 10.1128/aac.00204.
     PubMed     Abstract available
     
     
     
396. HOLLEY CL, Dhulipala V, Balthazar JT, Le Van A, et al
     A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance in Neisseria gonorrhoeae.
     Antimicrob Agents Chemother. 2022 Apr 25:e0025122. doi: 10.1128/aac.00251.
     PubMed     Abstract available
     
     
     
397. SALAMA OE, Gerstein AC
     Differential Response of Candida Species Morphologies and Isolates to Fluconazole and Boric Acid.
     Antimicrob Agents Chemother. 2022 Apr 21:e0240621. doi: 10.1128/aac.02406.
     PubMed     Abstract available
     
     
     
398. ROUCHON CN, Harris J, Zubair-Nizami Z, Weinstein AJ, et al
     The Cationic Antimicrobial Peptide Activity of Lysozyme Reduces Viable Enterococcus faecalis Cells in Biofilms.
     Antimicrob Agents Chemother. 2022 Apr 21:e0233921. doi: 10.1128/aac.02339.
     PubMed     Abstract available
     
     
     
399. SRIVASTAVA S, Boorgula GD, Wang JY, Huang HL, et al
     Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.
     Antimicrob Agents Chemother. 2022;66:e0232021.
     PubMed     Abstract available
     
     
     
400. POIREL L, Ortiz de la Rosa JM, Sadek M, Nordmann P, et al
     Impact of Acquired Broad-Spectrum beta-Lactamases on Susceptibility to Cefiderocol and Newly Developed beta-Lactam/beta-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
     Antimicrob Agents Chemother. 2022;66:e0003922.
     PubMed     Abstract available
     
     
     
401. RAJA SM, Guptill JT, Juel VC, Walter EB, et al
     First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E.
     Antimicrob Agents Chemother. 2022;66:e0173221.
     PubMed     Abstract available
     
     
     
402. TARACILA MA, Bethel CR, Hujer AM, Papp-Wallace KM, et al
     Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC beta-Lactamase.
     Antimicrob Agents Chemother. 2022;66:e0212421.
     PubMed     Abstract available
     
     
     
403. KUREPINA N, Chen L, Composto K, Rifat D, et al
     CRISPR Inhibition of Essential Peptidoglycan Biosynthesis Genes in Mycobacterium abscessus and Its Impact on beta-Lactam Susceptibility.
     Antimicrob Agents Chemother. 2022;66:e0009322.
     PubMed     Abstract available
     
     
     
404. LIPORAGI LOPES LC, Korangath P, Dos Santos SR Jr, Gabrielson KL, et al
     Bionized Nanoferrite Particles Alter the Course of Experimental Cryptococcus neoformans Pneumonia.
     Antimicrob Agents Chemother. 2022;66:e0239921.
     PubMed     Abstract available
     
     
     
405. MOON SM, Kim SY, Kim DH, Huh HJ, et al
     Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease.
     Antimicrob Agents Chemother. 2022;66:e0202721.
     PubMed     Abstract available
     
     
     
406. ANDRADE ESN, Brandao JG, Silva JSD, Coriolano CRF, et al
     Antimicrobial Resistance among Leprosy Patients in Brazil: Real-World Data Based on the National Surveillance Plan.
     Antimicrob Agents Chemother. 2022 Apr 18:e0217021. doi: 10.1128/aac.02170.
     PubMed     Abstract available
     
     
     
407. EICHENSEHER F, Herpers BL, Badoux P, Leyva-Castillo JM, et al
     Linker-Improved Chimeric Endolysin Selectively Kills Staphylococcus aureus In Vitro, on Reconstituted Human Epidermis, and in a Murine Model of Skin Infection.
     Antimicrob Agents Chemother. 2022 Apr 13:e0227321. doi: 10.1128/aac.02273.
     PubMed     Abstract available
     
     
     
408. CAFFREY AR, Appaneal HJ, LaPlante KL, Lopes VV, et al
     Impact of Clopidogrel on Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: a National Retrospective Cohort Study.
     Antimicrob Agents Chemother. 2022 Apr 13:e0211721. doi: 10.1128/aac.02117.
     PubMed     Abstract available
     
     
     
409. GARCIA-PRATS AJ, Frias M, van der Laan L, De Leon A, et al
     Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.
     Antimicrob Agents Chemother. 2022 Apr 11:e0214421. doi: 10.1128/aac.02144.
     PubMed     Abstract available
     
     
     
410. CHAUHAN U, Barth VC, Woychik NA
     tRNA(fMet) Inactivating Mycobacterium tuberculosis VapBC Toxin-Antitoxin Systems as Therapeutic Targets.
     Antimicrob Agents Chemother. 2022 Apr 11:e0189621. doi: 10.1128/aac.01896.
     PubMed     Abstract available
     
     
     
411. ZHANG T, Yu X, Wen S, Xue Y, et al
     Bone Penetration of Cycloserine in Osteoarticular Tuberculosis Patients of China.
     Antimicrob Agents Chemother. 2022 Apr 11:e0222421. doi: 10.1128/aac.02224.
     PubMed     Abstract available
     
     
     
412. VAN VLIET AHM, Thakur S, Prada JM, Mehat JW, et al
     Genomic Screening of Antimicrobial Resistance Markers in UK and US Campylobacter Isolates Highlights Stability of Resistance over an 18-Year Period.
     Antimicrob Agents Chemother. 2022 Apr 11:e0168721. doi: 10.1128/aac.01687.
     PubMed     Abstract available
     
     
     March 2022
413. LIN X, Qin X, Wu X, Liao Y, et al
     Markedly Increasing Antibiotic Resistance and Dual Treatment of Neisseria gonorrhoeae Isolates in Guangdong, China, from 2013 to 2020.
     Antimicrob Agents Chemother. 2022 Mar 29:e0229421. doi: 10.1128/aac.02294.
     PubMed     Abstract available
     
     
     
414. SONG N, Zhou X, Li D, Li X, et al
     A Proteomic Landscape of Candida albicans in the Stepwise Evolution to Fluconazole Resistance.
     Antimicrob Agents Chemother. 2022 Mar 28:e0210521. doi: 10.1128/aac.02105.
     PubMed     Abstract available
     
     
     
415. LI J, Coste AT, Bachmann D, Sanglard D, et al
     Deciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris.
     Antimicrob Agents Chemother. 2022 Mar 28:e0006722. doi: 10.1128/aac.00067.
     PubMed     Abstract available
     
     
     
416. TASNEEN R, Garcia A, Converse PJ, Zimmerman MD, et al
     Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
     Antimicrob Agents Chemother. 2022 Mar 22:e0239821. doi: 10.1128/aac.02398.
     PubMed     Abstract available
     
     
     
417. JI X, Kruger H, Wang Y, Fessler AT, et al
     Tn560, a Novel Tn554 Family Transposon from Porcine Methicillin-Resistant Staphylococcus aureus ST398, Carries a Multiresistance Gene Cluster Comprising a Novel spc Gene Variant and the Genes lsa(E) and lnu(B).
     Antimicrob Agents Chemother. 2022 Mar 22:e0194721. doi: 10.1128/aac.01947.
     PubMed    
     
     
     
418. DIDE-AGOSSOU C, Bauman AA, Ramey ME, Rossmassler K, et al
     Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
     Antimicrob Agents Chemother. 2022 Mar 21:e0231021. doi: 10.1128/aac.02310.
     PubMed     Abstract available
     
     
     
419. ROTHSTEIN TE, Cunningham SA, Rieke RA, Mainella JM, et al
     Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.
     Antimicrob Agents Chemother. 2022 Mar 21:e0243221. doi: 10.1128/aac.02432.
     PubMed     Abstract available
     
     
     
420. BILAL H, Tait JR, Lang Y, Zhou J, et al
     Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
     Antimicrob Agents Chemother. 2022;66:e0220321.
     PubMed     Abstract available
     
     
     
421. BLASCO L, Bleriot I, Gonzalez de Aledo M, Fernandez-Garcia L, et al
     Development of an Anti-Acinetobacter baumannii Biofilm Phage Cocktail: Genomic Adaptation to the Host.
     Antimicrob Agents Chemother. 2022;66:e0192321.
     PubMed     Abstract available
     
     
     
422. BUTLER MS, Gigante V, Sati H, Paulin S, et al
     Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.
     Antimicrob Agents Chemother. 2022;66:e0199121.
     PubMed     Abstract available
     
     
     
423. KURBATFINSKI N, Goodman SD, Bakaletz LO
     A Humanized Monoclonal Antibody Potentiates Killing of Diverse Biofilm-Forming Respiratory Tract Pathogens by Antibiotics.
     Antimicrob Agents Chemother. 2022;66:e0187721.
     PubMed     Abstract available
     
     
     
424. APPANEAL HJ, Lopes VV, LaPlante KL, Caffrey AR, et al
     Treatment, Clinical Outcomes, and Predictors of Mortality among a National Cohort of Admitted Patients with Acinetobacter baumannii Infection.
     Antimicrob Agents Chemother. 2022;66:e0197521.
     PubMed     Abstract available
     
     
     
425. LI Y, Zhang L, Xiu L, Wang D, et al
     A Multiplex Molecular Assay for Detection of Six penA Codons To Predict Decreased Susceptibility to Cephalosporins in Neisseria gonorrhoeae.
     Antimicrob Agents Chemother. 2022;66:e0170921.
     PubMed     Abstract available
     
     
     
426. SAWATZKY P, Demczuk W, Lefebvre B, Allen V, et al
     Increasing Azithromycin Resistance in Neisseria gonorrhoeae Due to NG-MAST 12302 Clonal Spread in Canada, 2015 to 2018.
     Antimicrob Agents Chemother. 2022;66:e0168821.
     PubMed     Abstract available
     
     
     
427. PALLIYIL S, Mawer M, Alawfi SA, Fogg L, et al
     Monoclonal Antibodies Targeting Surface-Exposed Epitopes of Candida albicans Cell Wall Proteins Confer In Vivo Protection in an Infection Model.
     Antimicrob Agents Chemother. 2022 Mar 14:e0195721. doi: 10.1128/aac.01957.
     PubMed     Abstract available
     
     
     
428. LI LH, Lu HF, Liu YF, Lin YT, et al
     FadACB and smeU1VWU2X Contribute to Oxidative Stress-Mediated Fluoroquinolone Resistance in Stenotrophomonas maltophilia.
     Antimicrob Agents Chemother. 2022 Mar 14:e0204321. doi: 10.1128/aac.02043.
     PubMed     Abstract available
     
     
     
429. BASARAB GS, Ghorpade S, Gibhard L, Mueller R, et al
     Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.
     Antimicrob Agents Chemother. 2022 Mar 10:e0219221. doi: 10.1128/aac.02192.
     PubMed     Abstract available
     
     
     
430. KLEINHENZ M, Beesetty P, Yang C, Li Z, et al
     Antibiotic Treatment of Staphylococcus aureus Infection Inhibits the Development of Protective Immunity.
     Antimicrob Agents Chemother. 2022 Mar 10:e0227021. doi: 10.1128/aac.02270.
     PubMed     Abstract available
     
     
     
431. SHELTON C, McNeil M, Allen R, Flint L, et al
     Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2022 Mar 9:e0204121. doi: 10.1128/aac.02041.
     PubMed     Abstract available
     
     
     
432. VAHEDI-SHAHANDASHTI R, Dietl AM, Binder U, Nagl M, et al
     Aspergillus terreus and the Interplay with Amphotericin B: from Resistance to Tolerance?
     Antimicrob Agents Chemother. 2022 Mar 7:e0227421. doi: 10.1128/aac.02274.
     PubMed     Abstract available
     
     
     
433. SCHARN CR, Tickler IA, Tenover FC, Goering RV, et al
     Characterization of SCCmec Instability in Methicillin-Resistant Staphylococcus aureus Affecting Adjacent Chromosomal Regions, Including the Gene for Staphylococcal Protein A (spa).
     Antimicrob Agents Chemother. 2022 Mar 7:e0237421. doi: 10.1128/aac.02374.
     PubMed     Abstract available
     
     
     February 2022
434. LEE JH, Park YE, Chong YP, Shim TS, et al
     Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.
     Antimicrob Agents Chemother. 2022;66:e0152221.
     PubMed     Abstract available
     
     
     
435. RUEDAS-LOPEZ A, Alonso-Garcia I, Lasarte-Monterrubio C, Guijarro-Sanchez P, et al
     Selection of AmpC beta-Lactamase Variants and Metallo-beta-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
     Antimicrob Agents Chemother. 2022;66:e0206721.
     PubMed     Abstract available
     
     
     
436. SELCHOW P, Ordway DJ, Verma D, Whittel N, et al
     Apramycin Overcomes the Inherent Lack of Antimicrobial Bactericidal Activity in Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2022;66:e0151021.
     PubMed     Abstract available
     
     
     
437. DAS S, Bush K
     Success and Challenges Associated with Large-Scale Collaborative Surveillance for Carbapenemase Genes in Gram-Negative Bacteria.
     Antimicrob Agents Chemother. 2022;66:e0229921.
     PubMed     Abstract available
     
     
     
438. TAKAMATSU A, Yaguchi T, Tagashira Y, Watanabe A, et al
     Nocardiosis in Japan: a Multicentric Retrospective Cohort Study.
     Antimicrob Agents Chemother. 2022;66:e0189021.
     PubMed     Abstract available
     
     
     
439. BIZOT E, Cointe A, Bidet P, Mariani-Kurkdjian P, et al
     Azithromycin Resistance in Shiga Toxin-Producing Escherichia coli in France between 2004 and 2020 and Detection of mef(C)-mph(G) Genes.
     Antimicrob Agents Chemother. 2022;66:e0194921.
     PubMed     Abstract available
     
     
     
440. CHUMBITA M, Puerta-Alcalde P, Gudiol C, Garcia-Pouton N, et al
     Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock.
     Antimicrob Agents Chemother. 2022;66:e0174421.
     PubMed     Abstract available
     
     
     January 2022
441. BERG A, Clary J, Hanna D, Nuermberger E, et al
     Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database.
     Antimicrob Agents Chemother. 2022 Jan 31:AAC0179321. doi: 10.1128/AAC.01793.
     PubMed     Abstract available
     
     
     
442. KAYA F, Ernest JP, LoMauro K, Gengenbacher M, et al
     A rabbit model to study antibiotic penetration at the site of infection for non-tuberculous mycobacterial lung disease: macrolide case study.
     Antimicrob Agents Chemother. 2022 Jan 31:aac0221221. doi: 10.1128/aac.02212.
     PubMed     Abstract available
     
     
     
443. KLINE A, Lionakis MS
     Case Commentary: Long-term fosmanogepix use in a transplant recipient with disseminated aspergillosis caused by azole-resistant Aspergillus calidoustus.
     Antimicrob Agents Chemother. 2022 Jan 24:aac0236821. doi: 10.1128/aac.02368.
     PubMed     Abstract available
     
     
     
444. DOMENECH P, Mouhoub E, Reed MB
     Experimental confirmation that an uncommon rrs gene mutation (g878a) of Mycobacterium tuberculosis confers resistance to streptomycin.
     Antimicrob Agents Chemother. 2022 Jan 24:AAC0191521. doi: 10.1128/AAC.01915.
     PubMed     Abstract available
     
     
     
445. KIMURA M, Asano-Mori Y, Sakoh T, Abe M, et al
     Factors associated with breakthrough fungemia caused by Candida, Trichosporon, or Fusarium species when the breakthrough fungemia developed in patients with hematological disorders.
     Antimicrob Agents Chemother. 2022 Jan 18:AAC0208121. doi: 10.1128/AAC.02081.
     PubMed     Abstract available
     
     
     
446. LEW C, Pellitteri Hahn M, Scarlett C, Rottier A, et al
     Proteomic Correlates of Enhanced Daptomycin Activity Following beta-Lactam Pre-Conditioning in Daptomycin-Resistant Methicillin-Resistant Staphylococcus aureus.
     Antimicrob Agents Chemother. 2022 Jan 18:AAC0201721. doi: 10.1128/AAC.02017.
     PubMed     Abstract available
     
     
     
447. BAO X, Bove M, Coenye T
     Organic Acids and Their Salts Potentiate the Activity of Selected Antibiotics against Pseudomonas aeruginosa Biofilms Grown in a Synthetic Cystic Fibrosis Sputum Medium.
     Antimicrob Agents Chemother. 2022;66:e0187521.
     PubMed     Abstract available
     
     
     
448. CRANE SD, Banerjee SK, Pechous RD
     Treatment with Fluticasone Propionate Increases Antibiotic Efficacy during Treatment of Late-Stage Primary Pneumonic Plague.
     Antimicrob Agents Chemother. 2022;66:e0127521.
     PubMed     Abstract available
     
     
     
449. PHAN JR, Do DM, Truong MC, Ngo C, et al
     An Aniline-Substituted Bile Salt Analog Protects both Mice and Hamsters from Multiple Clostridioides difficile Strains.
     Antimicrob Agents Chemother. 2022;66:e0143521.
     PubMed     Abstract available
     
     
     
450. WULLNER D, Gesper M, Haupt A, Liang X, et al
     Adaptive Responses of Pseudomonas aeruginosa to Treatment with Antibiotics.
     Antimicrob Agents Chemother. 2022;66:e0087821.
     PubMed     Abstract available
     
     
     
451. MCCONVILLE TH, Austin ED, Geng W, Shi Q, et al
     In Vitro Cytotoxicity and Clinical Correlates of MRSA Bacteremia.
     Antimicrob Agents Chemother. 2022;66:e0155921.
     PubMed     Abstract available
     
     
     
452. ARAGAW WW, Roubert C, Fontaine E, Lagrange S, et al
     Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice.
     Antimicrob Agents Chemother. 2022;66:e0140021.
     PubMed     Abstract available
     
     
     
453. BONNET PL, Le Gal S, Hoffmann CV, Morio F, et al
     Highly Conserved gsc1 Gene of Pneumocystis jirovecii in Patients with or without Prior Exposure to Echinocandins.
     Antimicrob Agents Chemother. 2022;66:e0156321.
     PubMed     Abstract available
     
     
     
454. ZHENG H, Wang Y, He W, Li F, et al
     In Vitro Activity of Pretomanid against Nontuberculous Mycobacteria.
     Antimicrob Agents Chemother. 2022;66:e0181021.
     PubMed    
     
     
     
455. YU R, Chen Z, Schwarz S, Yao H, et al
     Mobilization of tet(X4) by IS1 Family Elements in Porcine Escherichia coli Isolates.
     Antimicrob Agents Chemother. 2022;66:e0159721.
     PubMed     Abstract available
     
     
     
456. SINDELDECKER D, Prakash S, Stoodley P
     Exploration of the Pharmacodynamics for Pseudomonas aeruginosa Biofilm Eradication by Tobramycin.
     Antimicrob Agents Chemother. 2022;66:e0137121.
     PubMed     Abstract available
     
     
     
457. EALES BM, Tam VH
     Case Commentary: Novel Therapy for Multidrug-Resistant Acinetobacter baumannii Infection.
     Antimicrob Agents Chemother. 2022;66:e0199621.
     PubMed     Abstract available
     
     
     
458. ONG V, Wills S, Watson D, Sandison T, et al
     Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans.
     Antimicrob Agents Chemother. 2022;66:e0139021.
     PubMed     Abstract available
     
     
     
459. RAO S, Betancourt-Garcia M, Kare-Opaneye YO, Swierczewski BE, et al
     Critically Ill Patient with Multidrug-Resistant Acinetobacter baumannii Respiratory Infection Successfully Treated with Intravenous and Nebulized Bacteriophage Therapy.
     Antimicrob Agents Chemother. 2022;66:e0082421.
     PubMed     Abstract available
     
     
     
460. NICKLAS DA, Maggioncalda EC, Story-Roller E, Eichelman B, et al
     Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection.
     Antimicrob Agents Chemother. 2022;66:e0170421.
     PubMed     Abstract available
     
     
     
461. WARRYN L, Pluschke G
     Efficacy of an Acid-Oxidizing Solution against Mycobacterium ulcerans.
     Antimicrob Agents Chemother. 2022;66:e0087021.
     PubMed     Abstract available
     
     
     
462. SCHILDKRAUT JA, Coolen JPM, Burbaud S, Sangen JJN, et al
     RNA Sequencing Elucidates Drug-Specific Mechanisms of Antibiotic Tolerance and Resistance in Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2022;66:e0150921.
     PubMed     Abstract available
     
     
     
463. AMBATI S, Pham T, Lewis ZA, Lin X, et al
     DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis.
     Antimicrob Agents Chemother. 2022;66:e0146721.
     PubMed     Abstract available
     
     
     
464. D'AMICO H, Wallace KL, Burgess D, Burgess DS, et al
     Acute Kidney Injury Associated with Area under the Curve versus Trough Monitoring of Vancomycin in Obese Patients.
     Antimicrob Agents Chemother. 2022;66:e0088621.
     PubMed     Abstract available
     
     
     
465. KOELE SE, van Beek SW, Maartens G, Brust JCM, et al
     Optimized loading dose strategies for bedaquiline when restarting interrupted drug-resistant tuberculosis treatment.
     Antimicrob Agents Chemother. 2022 Jan 10:AAC0174921. doi: 10.1128/AAC.01749.
     PubMed     Abstract available
     
     
     
466. KILBURN S, Innes G, Quinn M, Southwick K, et al
     Antifungal Resistance Trends of Candida auris Clinical Isolates, New York-New Jersey, 2016-2020.
     Antimicrob Agents Chemother. 2022 Jan 10:aac0224221. doi: 10.1128/aac.02242.
     PubMed     Abstract available
     
     
     
467. VU BG, Moye-Rowley WS
     Azole-resistant alleles of ERG11 in Candida glabrata trigger activation of the Pdr1 and Upc2A transcription factors.
     Antimicrob Agents Chemother. 2022 Jan 10:AAC0209821. doi: 10.1128/AAC.02098.
     PubMed     Abstract available
     
     
     
468. WIRE MB, Jun SY, Jang IJ, Lee SH, et al
     A Phase 1 Study to Evaluate the Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Anti-Staphylococcal Lysin, LSVT-1701, in Healthy Adult Subjects.
     Antimicrob Agents Chemother. 2022 Jan 10:AAC0184221. doi: 10.1128/AAC.01842.
     PubMed     Abstract available
     
     
     
469. LONG H, Hu Y, Feng Y, Zong Z, et al
     Genome analysis of Klebsiella oxytoca complex for antimicrobial resistance and virulence genes.
     Antimicrob Agents Chemother. 2022 Jan 10:aac0218321. doi: 10.1128/aac.02183.
     PubMed     Abstract available
     
     
     
470. SMELTER D, Hayney M, Sakoulas G, Rose W, et al
     Is the Success of Cefazolin plus Ertapenem in Methicillin-Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin 1-beta?
     Antimicrob Agents Chemother. 2022 Jan 3:aac0216621. doi: 10.1128/aac.02166.
     PubMed     Abstract available
     
     
     December 2021
471. NAKANO S, Fujisawa T, Chang B, Ito Y, et al
     Whole-genome analysis-based phylogeographic investigation of Streptococcus pneumoniae serotype 19A sequence type 320 isolates in Japan.
     Antimicrob Agents Chemother. 2021 Dec 20:AAC0139521. doi: 10.1128/AAC.01395.
     PubMed     Abstract available
     
     
     
472. CAMARGO JF, Jabr R, Anderson AD, Lekakis L, et al
     Successful treatment of disseminated disease due to highly resistant Aspergillus calidoustus with a novel antifungal therapy.
     Antimicrob Agents Chemother. 2021 Dec 20:aac0220621. doi: 10.1128/aac.02206.
     PubMed     Abstract available
     
     
     
473. TRUONG-BOLDUC QC, Wang Y, Reedy JL, Vyas JM, et al
     Staphylococcus aureus Efflux Pumps and Tolerance to Ciprofloxacin and Chlorhexidine following Induction by Mupirocin.
     Antimicrob Agents Chemother. 2021 Dec 20:AAC0184521. doi: 10.1128/AAC.01845.
     PubMed     Abstract available
     
     
     
474. CHEN Y, Moran JC, Campbell-Lee S, Horsburgh MJ, et al
     Transcriptomic responses and survival mechanisms of staphylococci to the antimicrobial skin lipid sphingosine.
     Antimicrob Agents Chemother. 2021 Dec 13:AAC0056921. doi: 10.1128/AAC.00569.
     PubMed     Abstract available
     
     
     
475. LACKNER N, Vahedi-Shahandashti R, Jahnig S, Schonherr L, et al
     Echinocandins and their Activity against Aspergillus terreus Species Complex: A Novel Agar Screening Method.
     Antimicrob Agents Chemother. 2021 Dec 13:AAC0190921. doi: 10.1128/AAC.01909.
     PubMed     Abstract available
     
     
     
476. HUANG J, Guo S, Li X, Yuan F, et al
     Nemonoxacin enhances antibacterial activity and anti-resistant mutation ability of vancomycin against methicillin-resistant Staphylococcus aureus in an in vitro dynamic pharmacokinetic/pharmacodynamic model.
     Antimicrob Agents Chemother. 2021 Dec 13:AAC0180021. doi: 10.1128/AAC.01800.
     PubMed     Abstract available
     
     
     
477. AGUIAR-ALVES F, Le HN, Tran VG, Gras E, et al
     Anti-virulence Bispecific Monoclonal Antibody Mediated Protection Against Pseudomonas aeruginosa Ventilator-Associated Pneumonia in a Rabbit Model.
     Antimicrob Agents Chemother. 2021 Dec 13:AAC0202221. doi: 10.1128/AAC.02022.
     PubMed     Abstract available
     
     
     
478. LYONS MA
     Pharmacodynamics and the Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2021 Dec 6:AAC0163621. doi: 10.1128/AAC.01636.
     PubMed     Abstract available
     
     
     
479. KIM JS, Kim YH, Lee SH, Kim YH, et al
     Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2021 Dec 6:AAC0168421. doi: 10.1128/AAC.01684.
     PubMed     Abstract available
     
     
     
480. KHALIFA HO, Hubka V, Watanabe A, Nagi M, et al
     Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei recovered from an International Collection.
     Antimicrob Agents Chemother. 2021 Dec 6:AAC0185621. doi: 10.1128/AAC.01856.
     PubMed     Abstract available
     
     
     
481. VERMA R, Gurumurthy M, Yeo BCM, Lu Q, et al
     Effects of increasing concentrations of rifampicin on different Mycobacterium tuberculosis lineages in a Whole blood Bactericidal Activity Assay.
     Antimicrob Agents Chemother. 2021 Dec 6:AAC0169921. doi: 10.1128/AAC.01699.
     PubMed     Abstract available
     
     
     November 2021
482. POON R, Basuino L, Satishkumar N, Chatterjee A, et al
     Loss of GdpP function in Staphylococcus aureus leads to beta-lactam tolerance and enhanced evolution of beta-lactam resistance.
     Antimicrob Agents Chemother. 2021 Nov 29:AAC0143121. doi: 10.1128/AAC.01431.
     PubMed     Abstract available
     
     
     
483. SASAKI T, Svensson EM, Wang X, Wang Y, et al
     Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2021 Nov 29:AAC0160821. doi: 10.1128/AAC.01608.
     PubMed     Abstract available
     
     
     
484. CARVALHAES CG, Sader HS, Streit JM, Castanheira M, et al
     Activity of Oritavancin Against Gram-positive Pathogens Causing Bloodstream Infections in the United States Over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
     Antimicrob Agents Chemother. 2021 Nov 22:AAC0166721. doi: 10.1128/AAC.01667.
     PubMed     Abstract available
     
     
     
485. VOGENSEN VB, Bolhuis MS, Sturkenboom MGG, van der Werf TS, et al
     Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid resistant/intolerant tuberculosis patients.
     Antimicrob Agents Chemother. 2021 Nov 22:AAC0182921. doi: 10.1128/AAC.01829.
     PubMed     Abstract available
     
     
     
486. WEI J, Tong K, Wang H, Wen Y, et al
     Intra-articular vancomycin for the prophylaxis of periprosthetic joint infection caused by methicillin-resistant S. aureus after total knee arthroplasty in a rat model: the dosage, efficacy, and safety.
     Antimicrob Agents Chemother. 2021 Nov 22:AAC0164121. doi: 10.1128/AAC.01641.
     PubMed     Abstract available
     
     
     
487. LEE YL, Ko WC, Hsueh PR
     Geographic Patterns of Carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2015-2019.
     Antimicrob Agents Chemother. 2021 Nov 22:AAC0200021. doi: 10.1128/AAC.02000.
     PubMed     Abstract available
     
     
     
488. CRANDON JL, Kuti JL, Nicolau DP
     Erratum for Crandon et al., "Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model".
     Antimicrob Agents Chemother. 2021;65:e0187821.
     PubMed    
     
     
     
489. REITZEL RA, Rosenblatt J, Gerges BZ, Vargas-Cruz N, et al
     Erratum for Reitzel et al., "Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is Highly Effective In Vitro for Eradication of Candida auris Biofilms".
     Antimicrob Agents Chemother. 2021;65:e0198621.
     PubMed    
     
     
     
490. NEWMAN LM, Kankam M, Nakamura A, Conrad T, et al
     Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.
     Antimicrob Agents Chemother. 2021;65:e0129221.
     PubMed     Abstract available
     
     
     
491. JOUSSET AB, Oueslati S, Emeraud C, Bonnin RA, et al
     KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.
     Antimicrob Agents Chemother. 2021;65:e0116021.
     PubMed     Abstract available
     
     
     
492. FIGUEIREDO ABC, Fonseca FL, Kuczera D, Conte FP, et al
     Monoclonal Antibodies against Cell Wall Chitooligomers as Accessory Tools for the Control of Cryptococcosis.
     Antimicrob Agents Chemother. 2021;65:e0118121.
     PubMed     Abstract available
     
     
     
493. KERKEZ I, Tulkens PM, Tenson T, Van Bambeke F, et al
     Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an In Vitro Model of Intracellular Infection.
     Antimicrob Agents Chemother. 2021;65:e0146821.
     PubMed     Abstract available
     
     
     
494. MUHLEN S, Zapol'skii VA, Bilitewski U, Dersch P, et al
     Identification of Translocation Inhibitors Targeting the Type III Secretion System of Enteropathogenic Escherichia coli.
     Antimicrob Agents Chemother. 2021;65:e0095821.
     PubMed     Abstract available
     
     
     
495. VANSCOY BD, Lakota EA, Conde H, Fikes S, et al
     Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems.
     Antimicrob Agents Chemother. 2021;65:e0012221.
     PubMed     Abstract available
     
     
     
496. PEYRUSSON F, Whelan AO, Hartley MG, Norville IH, et al
     Intracellular Activity of Antibiotics against Coxiella burnetii in a Model of Activated Human THP-1 Cells.
     Antimicrob Agents Chemother. 2021;65:e0106121.
     PubMed     Abstract available
     
     
     
497. KELLY MC, Yeager SD, Shorman MA, Wright LR, et al
     Incidence and Predictors of Gram-Negative Bacilli in Hospitalized People Who Inject Drugs with Injection Drug Use-Attributable Infections.
     Antimicrob Agents Chemother. 2021;65:e0092521.
     PubMed     Abstract available
     
     
     
498. SORAYAH R, Moraski GC, Barkan D, Pethe K, et al
     The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2021;65:e0096421.
     PubMed     Abstract available
     
     
     
499. MARTINS O, Lee J, Kaushik A, Ammerman NC, et al
     In Vitro Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2021;65:e0154521.
     PubMed     Abstract available
     
     
     
500. LI D, Sabato PE, Guiastrennec B, Ouerdani A, et al
     Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections.
     Antimicrob Agents Chemother. 2021;65:e0089521.
     PubMed     Abstract available
     
     
     
501. SINGULANI JL, Oliveira LT, Ramos MD, Fregonezi NF, et al
     The Antimicrobial Peptide MK58911-NH2 Acts on Planktonic, Biofilm, and Intramacrophage Cells of Cryptococcus neoformans.
     Antimicrob Agents Chemother. 2021;65:e0090421.
     PubMed     Abstract available
     
     
     
502. SHARMA D, Paul RA, Rudramurthy SM, Kashyap N, et al
     Impact of FKS1 genotype on echinocandin in-vitro susceptibility in Candida auris and in-vivo response in a murine model of infection.
     Antimicrob Agents Chemother. 2021 Nov 15:AAC0165221. doi: 10.1128/AAC.01652.
     PubMed     Abstract available
     
     
     
503. NIIMI M, Niimi K, Tanabe K, Cannon RD, et al
     Inhibitor Resistant Mutants Give Important Insights into Candida albicans ABC Transporter Cdr1 Substrate Specificity and Help Elucidate Efflux Pump Inhibition.
     Antimicrob Agents Chemother. 2021 Nov 15:AAC0174821. doi: 10.1128/AAC.01748.
     PubMed     Abstract available
     
     
     
504. YAMAMURO R, Kimura M, Asano-Mori Y, Abe M, et al
     Clinical and microbiological characteristics of proven invasive aspergillosis due to rare/cryptic species in allogeneic hematopoietic stem cell transplant recipients.
     Antimicrob Agents Chemother. 2021 Nov 15:AAC0163021. doi: 10.1128/AAC.01630.
     PubMed     Abstract available
     
     
     
505. YU JF, Xu JT, Yang SS, Gao MN, et al
     Decreased methylenetetrahydrofolate reductase activity leads to increased sensitivity to para-aminosalicylic acid in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2021 Nov 15:AAC0146521. doi: 10.1128/AAC.01465.
     PubMed     Abstract available
     
     
     
506. RIVAS L, Alcalde-Rico M, Martinez JR, Moreno V, et al
     Real-world Performance of Susceptibility Testing for Ceftolozane/Tazobactam Against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.
     Antimicrob Agents Chemother. 2021 Nov 15:AAC0165721. doi: 10.1128/AAC.01657.
     PubMed     Abstract available
     
     
     
507. PHAN MD, Peters KM, Alvarez Fraga L, Wallis SC, et al
     Plasmid-mediated ciprofloxacin resistance imparts a selective advantage on Escherichia coli ST131.
     Antimicrob Agents Chemother. 2021 Nov 15:AAC0214621. doi: 10.1128/AAC.02146.
     PubMed     Abstract available
     
     
     
508. LIAO YS, Chen BH, Teng RH, Wang YW, et al
     Antimicrobial resistance in Campylobacter coli and Campylobacter jejuni from human campylobacteriosis in Taiwan, 2016-2019.
     Antimicrob Agents Chemother. 2021 Nov 8:AAC0173621. doi: 10.1128/AAC.01736.
     PubMed     Abstract available
     
     
     
509. MORRISETTE T, Lev KL, Canfield GS, Duerkop BA, et al
     Evaluation of Bacteriophage Cocktails Alone and in Combination with Daptomycin Against Daptomycin-Nonsusceptible Enterococcus faecium.
     Antimicrob Agents Chemother. 2021 Nov 1:AAC0162321. doi: 10.1128/AAC.01623.
     PubMed     Abstract available
     
     
     
510. KARAU MJ, Schmidt-Malan SM, Cunningham SA, Mandrekar JN, et al
     Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.
     Antimicrob Agents Chemother. 2021 Nov 1:AAC0170321. doi: 10.1128/AAC.01703.
     PubMed     Abstract available
     
     
     October 2021
511. HERREN SC, Huemer M, Acevedo CT, Gomez-Mejia A, et al
     Assessing antibiotic tolerance of Staphylococcus aureus derived directly from patients by the Replica Plating Tolerance Isolation System - REPTIS.
     Antimicrob Agents Chemother. 2021 Oct 25:AAC0096721. doi: 10.1128/AAC.00967.
     PubMed     Abstract available
     
     
     
512. ANAHTAR MN, Bramante JT, Xu J, Desrosiers LA, et al
     Prediction of antimicrobial resistance in clinical Enterococcus faecium isolates using a rules-based analysis of whole genome sequences.
     Antimicrob Agents Chemother. 2021 Oct 25:AAC0119621. doi: 10.1128/AAC.01196.
     PubMed     Abstract available
     
     
     
513. BUTCHER MC, Brown JL, Hansom D, Wilson-Van Os R, et al
     Antifungal loaded calcium sulfate beads as a potential therapeutic in combating Candida auris.
     Antimicrob Agents Chemother. 2021 Oct 25:AAC0171321. doi: 10.1128/AAC.01713.
     PubMed     Abstract available
     
     
     
514. MISHRA NN, Lew C, Abdelhady W, Lapitan CK, et al
     Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant S. aureus: In vitro, Ex vivo and In vivo Metrics.
     Antimicrob Agents Chemother. 2021 Oct 25:AAC0164921. doi: 10.1128/AAC.01649.
     PubMed     Abstract available
     
     
     
515. DEMCZUK W, Martin I, Griffith A, Lefebvre B, et al
     Linear regression equations to predict beta-lactam, macrolide, lincosamide and fluoroquinolone minimum inhibitory concentrations from molecular antimicrobial resistance determinants in Streptococcus pneumoniae.
     Antimicrob Agents Chemother. 2021 Oct 18:AAC0137021. doi: 10.1128/AAC.01370.
     PubMed     Abstract available
     
     
     
516. BAKLOUTI S, Marolleau S, Chavanet P, Bonnet E, et al
     Letter to the Editor on: "Population Pharmacokinetics of Dalbavancin and Dosing Considerations for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections".
     Antimicrob Agents Chemother. 2021 Oct 18:AAC0149321. doi: 10.1128/AAC.01493.
     PubMed     Abstract available
     
     
     
517. CAFLISCH KM, Patel R
     Phage Activity Against Planktonic and Biofilm Staphylococcus aureus Periprosthetic Joint Infection Isolates.
     Antimicrob Agents Chemother. 2021 Oct 18:AAC0187921. doi: 10.1128/AAC.01879.
     PubMed     Abstract available
     
     
     
518. JIANG S, Zhuang H, Zhu F, Wei X, et al
     The role of mprF mutations in "see-saw effect" of Daptomycin-resistant methicillin-resistant Staphylococcus aureus isolates.
     Antimicrob Agents Chemother. 2021 Oct 18:AAC0129521. doi: 10.1128/AAC.01295.
     PubMed     Abstract available
     
     
     
519. BAGHDADI JD, Coffey KC, Adediran T, Goodman KE, et al
     Antibiotic Use and Bacterial Infection among Inpatients in the First Wave of COVID-19: a Retrospective Cohort Study of 64,691 Patients.
     Antimicrob Agents Chemother. 2021;65:e0134121.
     PubMed     Abstract available
     
     
     
520. SHORTRIDGE D, Arends SJR, Streit JM, Castanheira M, et al
     Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens.
     Antimicrob Agents Chemother. 2021;65:e0126421.
     PubMed     Abstract available
     
     
     
521. TALLEY AK, Thurston A, Moore G, Gupta VK, et al
     First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections.
     Antimicrob Agents Chemother. 2021;65:e0120821.
     PubMed     Abstract available
     
     
     
522. FONTANA H, Cardoso B, Esposito F, de Lima AV, et al
     Small IncQ1 Plasmid Encoding KPC-2 Expands to Invasive Nontyphoidal Salmonella.
     Antimicrob Agents Chemother. 2021;65:e0155221.
     PubMed    
     
     
     
523. GUO Q, Xu L, Tan F, Zhang Y, et al
     A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro.
     Antimicrob Agents Chemother. 2021;65:e0088921.
     PubMed     Abstract available
     
     
     
524. KOMM O, Almeida DV, Converse PJ, Omansen TF, et al
     Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer.
     Antimicrob Agents Chemother. 2021;65:e0141821.
     PubMed     Abstract available
     
     
     
525. BANERJEE R, Cunningham SA, Beisken S, Posch AE, et al
     Core Genome Multilocus Sequence Typing and Prediction of Antimicrobial Susceptibility Using Whole-Genome Sequences of Escherichia coli Bloodstream Infection Isolates.
     Antimicrob Agents Chemother. 2021;65:e0113921.
     PubMed     Abstract available
     
     
     
526. RUBINO CM, Flanagan S
     Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections.
     Antimicrob Agents Chemother. 2021;65:e0084221.
     PubMed     Abstract available
     
     
     
527. LOVEY A, Krel M, Borchardt A, Brady T, et al
     Development of Novel Immunoprophylactic Agents against Multidrug-Resistant Gram-Negative Bacterial Infections.
     Antimicrob Agents Chemother. 2021;65:e0098521.
     PubMed     Abstract available
     
     
     
528. STOTT KE, Le T, Nguyen T, Whalley S, et al
     Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.
     Antimicrob Agents Chemother. 2021;65:e0063621.
     PubMed     Abstract available
     
     
     
529. CLAY KA, Hartley MG, Armstrong S, Bewley KR, et al
     Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever.
     Antimicrob Agents Chemother. 2021;65:e0067321.
     PubMed     Abstract available
     
     
     
530. ZAIDAN N, Hornak JP, Reynoso D
     Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination.
     Antimicrob Agents Chemother. 2021;65:e0092421.
     PubMed     Abstract available
     
     
     
531. CUBRIA MB, Vega LA, Shropshire WC, Sanson MA, et al
     Population genomics reveals distinct temporal association with the emergence of ST1 serotype V Group B Streptococcus and macrolide resistance in North America.
     Antimicrob Agents Chemother. 2021 Oct 11:AAC0071421. doi: 10.1128/AAC.00714.
     PubMed     Abstract available
     
     
     
532. WILLIAMSON B, Wilk A, Guerrero KD, Mikulski TD, et al
     Impact of Erg11 amino acid substitutions identified in Candida auris clade III isolates on triazole drug susceptibility.
     Antimicrob Agents Chemother. 2021 Oct 11:AAC0162421. doi: 10.1128/AAC.01624.
     PubMed     Abstract available
     
     
     
533. EVERT BJ, Slesarenko VA, Punnasseril JMJ, Taha, et al
     Self-inhibitory peptides targeting the Neisseria gonorrhoeae MtrCDE efflux pump increase antibiotic susceptibility.
     Antimicrob Agents Chemother. 2021 Oct 11:AAC0154221. doi: 10.1128/AAC.01542.
     PubMed     Abstract available
     
     
     
534. GANAPATHY US, Del Rio RG, Cacho-Izquierdo M, Ortega F, et al
     A Mycobacterium tuberculosis NBTI DNA gyrase inhibitor is active against Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2021 Oct 4:AAC0151421. doi: 10.1128/AAC.01514.
     PubMed     Abstract available
     
     
     
535. JACQUELINE C, Caillon J, Meyer O, Dailly E, et al
     Efficacy of Nano-Encapsulated Daptomycin in an Experimental Methicillin-Resistant Staphylococcus aureus (MRSA) Bone and Joint Infection Model.
     Antimicrob Agents Chemother. 2021 Oct 4:AAC0076821. doi: 10.1128/AAC.00768.
     PubMed     Abstract available
     
     
     
536. RADTKE KK, Ernest JP, Zhang N, Ammerman NC, et al
     Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modelling study.
     Antimicrob Agents Chemother. 2021 Oct 4:AAC0170521. doi: 10.1128/AAC.01705.
     PubMed     Abstract available
     
     
     
537. IKEDA T, Suzuki R, Jin W, Wachino JI, et al
     Isolation of Group A Streptococci with Reduced In Vitro beta-Lactam Susceptibility Harboring Amino Acid Substitutions in Penicillin-Binding Proteins in Japan.
     Antimicrob Agents Chemother. 2021 Oct 4:AAC0148221. doi: 10.1128/AAC.01482.
     PubMed     Abstract available
     
     
     September 2021
538. DIAZ-GARCIA J, Mesquida A, Gomez A, Machado M, et al
     Antifungal susceptibility testing identifies the abdominal cavity as a source of Candida glabrata resistant isolates.
     Antimicrob Agents Chemother. 2021 Sep 27:AAC0124921. doi: 10.1128/AAC.01249.
     PubMed     Abstract available
     
     
     
539. ALMEIDA D, Converse PJ, Li SY, Upton AM, et al
     Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis.
     Antimicrob Agents Chemother. 2021 Sep 27:AAC0141221. doi: 10.1128/AAC.01412.
     PubMed     Abstract available
     
     
     
540. INGLE DJ, Andersson P, Valcanis M, Wilmot M, et al
     Genomic epidemiology and antimicrobial resistance mechanisms of imported typhoid in Australia.
     Antimicrob Agents Chemother. 2021 Sep 20:AAC0120021. doi: 10.1128/AAC.01200.
     PubMed     Abstract available
     
     
     August 2021
541. HOWARD-ANDERSON J, van Duin D
     Uncertainty in evaluating treatment outcomes in carbapenem-resistant Acinetobacter baumannii infections.
     Antimicrob Agents Chemother. 2021 Aug 23:AAC0142421. doi: 10.1128/AAC.01424.
     PubMed     Abstract available
     
     
     
542. MUKHERJEE S, Blankenship HM, Rodrigues JA, Mosci RE, et al
     Antibiotic susceptibility profiles and frequency of resistance genes in clinical Shiga toxin-producing Escherichia coli isolates from Michigan over a 14-year period.
     Antimicrob Agents Chemother. 2021 Aug 23:AAC0118921. doi: 10.1128/AAC.01189.
     PubMed     Abstract available
     
     
     
543. GILL CM, Aktathorn E, Alfouzan W, Bourassa L, et al
     Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.
     Antimicrob Agents Chemother. 2021 Aug 16:AAC0120421. doi: 10.1128/AAC.01204.
     PubMed     Abstract available
     
     
     
544. NGWALERO P, Brust JCM, van Beek SW, Wasserman S, et al
     Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB.
     Antimicrob Agents Chemother. 2021 Aug 9:AAC0239920. doi: 10.1128/AAC.02399.
     PubMed     Abstract available
     
     
     
545. GUTIERREZ-GUTIERREZ B, Perez-Nadales E, Perez-Galera S, Fernandez-Ruiz M, et al
     Ertapenem for treatment of non-severe bacteremic urinary-tract infections due to ESBL-producing Enterobacterales in kidney transplant recipients: a propensity score and DOOR-based analysis.
     Antimicrob Agents Chemother. 2021 Aug 9:AAC0110221. doi: 10.1128/AAC.01102.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Bacterial Infections and Mycoses is free of charge.